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The work presented for examination in this thesis concerns the investigation 
a'-'J management of patients with stroke. The underlying theme which ^cites 
the chapters is that of outcome following stroke, and how it may be influenced 
or predicted.
Chapter one is a broad overview of stroke disease, incorporating a brief 
summary of the socio-economic burden of stroke in the Western world. The 
clinical features and mechanisms of acute ischaemic stroke are discussed, 
and primary and secondary preventative measures are outlined. Each of the 
clinical, biochemical and radiological factors discussed later in the thes s is 
introduced, and for each topic a synopsis of earlier published work is 
presented. As chapter six deals with a novel magnetic resonance imaging 
sequence, chapter one also contains a summary of the basic physical 
principles of magnetic resonance.
Chapter two reports a randomised, double blind placebo-controlled study
designed to investigate the effect of the angiotensin converting enzyme 
inhibitor perindopril upon cerebral and renal perfusion in hypertensive stroke 
patients with carotid artery disease. Control of hypertension in this group of 
patients is associated with the theoretical risk of reduction in cerebral 
perfusion distal to a stenotic lesion of the internal carotid artery; however 
failure to reduce elevated levels of blood pressure is associated with 
significant morbidity. Perindopril reduces blood pressure but not ce re c-a I 
perfusion in hypertensive patients with recent ischaemic stroke, although the
iV
mechanistic basis of this observation is unclear. ( hypothesised that 
perindopril would lower blood pressure but not cerebral or renal perfusion in 
patients with ischae"" :  stroke accompanied by significant carotid arterial 
disease. Transcranial and duplex Doppler ultrasound were used to monitor 
global cerebral blood flow; regional cerebral perfusion was assessed using 
99mTc hexamethyl propylene amine oxide single photon emission computed 
tomography (HMPAO SPECT) and dynamic HMPAO bolus imaging 
techniques, Glomerular filtration rate was measured using ^'Chromium EDTA. 
With a sample size of 24 patients we expected to detect a difference in 
internal carotid artery flow (as assessed by carotid Doppler) of 16% with 80% 
power.
Patients were identified at our cerebrovascular clinic, and after consent was 
obtained they were randomised to receive either perindopril 4mg daily for 14
days or placebo. Regular measurements of blood pressure, internal carotid 
artery velocity, internal carotid artery diameter and middle cerebral artery 
velocity were made before and at regular intervals for 24 hours after dosing. 
SPECT scanning was performed before dosing and at time of peak drug 
effect (6-8 hours after dose).
Blood pressure was effectively reduced in the treated group, and no fall in 
cerebral perfusion or drug associated neurological deterioration was 
observed. The glomerular filtration rate of one patient in the treated group fell
after administration of oerindoprii: treatment was withdrawn and the patient
was well at the conclusion of the study. In the other patients, GFR was
unchanged.
I conclude that although perindopril lowers blood pressure without affecting 
cerebral perfusion in this population, screening for renal artery stenosiS 
should be considered before treatment is introduced.
Chapter three reports a study to investigate the feasibility of rigorous control 
of blood glucose in hyperglycaemic patients following stroke. Hyperglycaem.a 
(blood glucose concentration greater than 8.0 mmol/L) at the time of 
ischaemic stroke has been identified as an independent poor prognostic 
factor, equivalent to adding 20 years to the patient's age. A randomised, 
controlled trial to investigate the potential benefit of blood glucose lowering in 
the context o f acute ischaemic stroke is warranted, and we sought to 
investigate the feasibility of one approach.
After obtaining informed consent, 24 patients presenting within 12 hours of 
onset of acute ischaemic stroke with blood glucose greater than or equal to 8 
mmol/lit and no requirement for insulin were randomised to receive either 
standard control of blood sugar or rigorous glycaemic control using 
intravenous insulin administered according to a predetermined sliding scale 
Treatment was maintained for 48 hours after admission. The study was 
performed on an open label basis due to practical difficulties in titrating a 
placebo infusion. Patients in both arms of the study received infusion c" 
intravenous crystalloid at a rate determined by their fluid balance and
metabolic status; blood glucose was measured two-hourly in all patients for 48 
hours. Normal diet was permitted if swallowing was safe, however no tube 
feeding was permitted fm the duration of the ir.Gsion. Patiems were reviewed 
at one month after admission, and clinical parameters were recorded.
The sliding scale regime was found to be well tolerated by patients, with only 
one episode of symptoms consistent with iatrogenic hypoglycaemia. Blood 
glucose concentration in the treated group was lower, with significant 
reduction in area under the glucoseHime curve. A larger efficacy study to 
investigate the effect of intervention with insulin in such patients is warranted.
The prognostic significance of triglyceride concentration following ischaemic 
stroke is investigated in chapter four. Recent data have shown an unexpected 
association between poor acute stroke outcome and lower serum cholesterol. 
Triglyceride concentration has been linked to coronary heart disease and 
stroke; however there are currently no data on the relationship between 
triglyceride and stroke outcome. Such information may yield further 
mechanistic information on the relationship between lipids and stroke 
outcome.
I studied 1312 non-diabetic patients presenting to our acute stroke unit with 
computed tomography confirmed acute stroke. Fasting blood samples were 
drawn within 24 hours of admission for glucose, lipids and a standard battery 
of biochemistry and hematological tests. Information on age, stroke type, 
admission blood pressure, smoking status, presence of atrial fibrillation,
Vll
resolution time of symptoms and Oxfordshire Community Stroke Project 
clinical classification was collated. Stepwise oroportional hazards regression 
was used ‘o estimate the effect of the above variables on survival following 
stroke.
Increased age (p<0.0001), presence of atrial fibrillation (p=0.009), 
hyperglycemia (p=0.001), and lower triglyceride level (p<0.0001)
In chapter five the prognostic significance of visible infarction on computed 
tomography in patients with lacunar stroke is examined. The functional 
outcome of patients with lacunar stroke is variable, and relatively few 
prognostic factors have been identified. All patients presenting to our unit with
independently predicted higher mortality; early resolution of symptoms 
(p=0.004) was independently associated with lower mortality. Although serum 
cholesterol level predicted outcome after adjusting for other prognostic 
factors, it did not remain significant when triglyceride level was entered in the 
model. The relative hazard per additional quartiie of triglyceride was 0.84 
(95% confidence interval 0.77 to 0.92).
I conclude that low triglyceride concentration strongly predicts higher mortality 
following stroke, whereas serum cholesterol level is not an independent 
predictor. Outcome following stroke thus relates more strongly to triglyceride- 
rich than to cholesterol-rich lipoprotein concentrations. The mechanisms 
which underlie this observation require further investigation.
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In chapter five the prognostic significance of visible infarction on computed 
tomography in patients with lacunar stroke is examined. The functional
lacunar symptcms between June 1990 and February 1998 were identified. 
Patients with '^on-vascular causes for the symptoms, patients imaged with 
MRi and pa" e-ts imaged within 12 hours of onset of symptoms were 
excluded from the analysis. 404 remaining patients were divided into two 
groups: “CT p:sitive ‘’ if the scan showed an appropriately-placed area of 
cerebral infarction, and "CT negative” if the scan showed no such lesion. 
Survival times in patients with and without visible infarction on CT were 
compared using a log-rank test. A proportional hazards model was then used 
to assess the ertect of visible infarction on survival after correcting for other 
clinical and biocnemical factors known or suspected to influence prognosis.
No significant difference in duration of hospital stay, survival or functional 
outcome was seen between the two groups. 1 conclude that the presence of 
visible infarction on CT does not influence prognosis after lacunar stroke.
In chapter six the development and implementation of a novel diffusion- 
weighted magnetic resonance sequence is reported. Diffusion-weighted 
imaging (DW-MRI) is highly sensitive to changes in the apparent diffusion of 
water that occur in regions of cerebral ischaemia, allowing identification of 
ischaemic brain damage much earlier than was previously possible with 
conventional sequences. Previously reported diffusion-weighted sequences 
have required powerful (1.5T) magnets and Echo-planar capabilities or else 
have severe morion artefact sensitivity. We have developed a time-reversed 
steady state (PSIF) diffusion-weighted sequence which uses a 1.0T magnet 
and does not require echo-planar capabilities.
IX
Nine consecutive patients with acute ischaemic stroke were scanned within 8 
hours of onset of symptoms Mes an age was 66.5 years range 50 - 83. All 
patients were scanned with the PSIF sequence, followed by conventional T2- 
weighted imaging. In all cases, lesions were seen on DWI that were not seen 
on the T2 images. The median time from symptom onset to scan was 5 hours 
55 minutes (Range 2 hours 35 minutes to 7 hours 10 minutes). Localisation 
in each of these cases assisted medical management. In 2 cases, more than 
one lesion was present in each individual. The diffusion-weighted images 
allowed the new lesion to be discriminated from older lesions.
We conclude that the DW-PSIF sequence represents a clinically useful means 
of imaging acute ischaemic stroke at 1.0T, providing more diagnostic 
information than T2 weighted imaging alone. The sequence does not require 
high magnetic field strength or echo-planar capabilities, and has the potential 
to be widely applied in centres previously unable to use diffusion-weighted 
MRI due to technical limitations.
'" '.it
In chapter seven, preliminary experience with the use of recombinant tissue
,plasminogen activator in a UK stroke centre is reported. No treatment for 
acute ischaemic stroke is currently licensed for use in the United Kingdom, 
and the use of thrombolytic therapy is restricted to a small number of 
specialist centres, where it is employed outwith licence.
Patients were selected and treated in accordance with the American Heart 
Association guidelines. NIH, Barthei and Rankin scores were prospectively 
measured on admission at three days and at three mo^:ns for all patients 
with stroke treated with rt-PA in our unit between April 1997 and November 
1998. Intracranial and systemic haemorrhagic complications were recorded.
Six women and nine men received thrombolytic treatment, mean age 74 years 
(58-93). Initial median NIH score was 19 (range 5-30). Nine patients had 
symptoms consistent with a total anterior circulation infarction. There were 
three cases of partial anterior circulation infarct, two lacunar infarcts and one 
posterior circulation infarct. One patient received two doses of rt-PA on 
separate occasions. Fourteen of the fifteen recipients survived until day 3. 
Among this group, median NIH score fell by six points (SD 7.9). Eleven of 
fifteen recipients survived until month 3. Median NIH score in this group fell by 
11 points (SD 7.6). Two patients died of cerebral oedema complicating 
massive cerebral infarction, two of hypostatic bronchopneumonia. Bleeding 
complications consisted of one systemic episode and one asymptomatic 
intracranial haemorrhage. At three months, four patients had Barthei scores 
of 95-100, four had scores of 55-90 and three were below 50.
Our experience with rt-PA in a UK stroke unit is consistent with that of the 
NINDS study investigators. No inferences concerning efficacy can be made 
due to the small numbers involved; however despite initial severity of stroke, 
47% of those treated were alive and at home at three months.
XI
Xll
Chapter eight contains a synopsis of the work presented, together with a brief 
discussion of the results in the context of our current understanding of stroke 
disease Future directions of study arismg from the research are identified and 
discussed.
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1.01 The burden of stroke
Stroke is among the most important causes of severe disability in the Western 
world and is the third leading cause of death lafter coronary heart Otsease 
and cancer) in most Western countries. The condition has a profound social 
and economic effect on the affected patient, the relatives of the patient, and 
on society as a whole. In the United Kingdom, stroke disease consumes a 
substantial proportion of health service resources directly, and is responsible 
for many less obvious costs. Although stroke patients account for only 2% of 
hospital discharges in Scotland, 4.6% of all Scottish health service costs are 
used in the care of patients with stroke,^ and patients with stroke account for 
7% of Scottish hospital bed-days. The considerable financial costs to the 
health service are relatively easy to measure; however the enormous burden 
borne by society as a whole is more difficult to estimate. Approximately one 
quarter of patients with stroke are below retirement age, leading to direct loss 
of income and to indirect costs such as reduced national productivity. In 
addition, much of the long-term care afforded to patients disabled by stroke 
disease is provided by family members, and to date little effort has been made 
to define the level and specific nature of the burden borne by relatives of 
stroke patients.^ Recognition of the cost of stroke to society has raised the 
profile of stroke care in the United Kingdom, and emphasised the importance 
of the delivery of quality stroke care in a cost-effective manner.'^ In 1992 
improved stroke care was identified as a priority in the improvement of the 
Health of the Nation.^ A number of subsequent studies have demonstrated 
the benefit of organised hospital-based stroke services upon stroke 
mortality®^® and long-term dependency.® Unfortunately the heterogeneous
13
nature of the stroke units studied made it difficult to identify which facets of the 
package of care provided by stroke units were of particular benefit. It is likely 
that expert physical réhabilitation and secondary prevention with antiplatelet 
agents, anticoagulants and carotid endarterectomy contributed to the better 
outcome enjoyed by patients treated in dedicated stroke units; however it is 
likely that other less tangible benefits of the multidisciplinary approach exist 
and have yet to be identified.
The challenge of reducing the burden of stroke to society is huge, and will not 
be met solely by improving the initial and secondary preventative care offered 
to patients with stroke. Primary stroke prevention is potentially the most 
effective method of reducing overall stroke-related morbidity and mortality, 
and the importance of risk factor intervention such as blood pressure control, 
smoking cessation, and appropriate management of predisposing cardiac 
disease has become apparent over recent years. Although both primary and 
secondary preventative strategies have improved, the progressive rise in the 
number of elderly people in W estern countries leads to the conclusion that the 
burden of stroke will remain a significant health and socio-economic problem 
for many years to come. The following chapters will consider a number of 
metabolic, radiological and therapeutic factors which may influence outcome 
following ischaemic stroke. The purpose of this introductory chapter is to 
provide a background to the main themes discussed later in the thesis.
14
1.02 Stroke diagnosis
The diagnosis of stroke usually begins with identification of a foca’ 
neurological deficit. The initial encounte- with me patient should achieve 
several aims:
i) Confirmation of the vascular nature of the lesion.
ii) Identification of the location and extent of the cerebral damage.
iii) Institution of appropriate treatment to minimise ongoing cerebral 
damage.
iv) An indication of the likely aetiology of the event,
Subsequent interaction with the patient should involve:
i) Institution of appropriate secondary preventative measures to prevent 
subsequent vascular events.
ii) Recognition of existing co-morbidity and anticipation of development of 
known complications of stroke disease such as deep venous 
thrombosis.
The main differential diagnoses of cerebrovascular disease are seizure 
activity and migraine. In the elderly, systemic infections such as urinary tract 
sepsis may present with neurological symptoms which may be confused with 
cerebral ischaemia. Sufficient information to exclude these possibilities may 
usually be obtained from a detailed history from the patient or witnesses. 
Further alternative causes of focal neurological deficit include cerebral space 
occupying lesion such as subdural haemorrhage or tumour, metabolic 
disturbance such as hypo or hyperglycaem^a, infections such as encephalitis 
or cerebral abscess, hypertensive encephalopathy, syncope, or
15
demyelination. In many cases further clarification with brain imaging or blood 
tests may be required before the vascular nature of the symptoms can be 
identified
Having identified cerebrovascular disease as the likely underlying pathology, 
attention should be turned to the nature of the vascular lesion. It is important 
to distinguish cerebral haemorrhage from cerebral infarction at an early stage, 
due to profound differences w the management of these conditions. Many 
scales designed to allow differentiation of ischaemic stroke from cerebral 
haemorrhage on clinical grounds have been proposed;^ however none 
has been shown to be reliable, and in some cases may be frankly
I
imisleading/^ Brain imaging is necessary reliably to exclude cerebral 
haemorrhage. Conventional x-ray computed tomography will reliably detect 
intracerebral haemorrhage within two weeks of stroke; however if more than 
two weeks has elapsed since ictus, involutional change within the 
intracerebral haematoma makes haemorrhage hard to distinguish from infarct
3I
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using this imaging modality, and magnetic resonance imaging may be 
required.
In most cases, clinical examination allows reasonable estimation of the 
location and extent of cerebral damage following stroke. The majority of 
symptoms arising as a result of stroke can be attributed to dysfunction of an 
identifiable area of brain, for example monoparesis following infarction of a 
discrete area of motor cortex Other symptoms arising as a result of stroke 
may be less easy to categorise; isolated dysarthria, vertigo, confusion and
16
cognitive disturbance such as amnesia may all reflect focal neurological 
dysfunction but may also occur as a result of a more diffuse cerebral insult. 
Localisation of cerebral infarction ma> ;.e!d informa: on concerning the 
underlying aetiology of the stroke, which in turn may influence further 
management. Patients with ischaemic stroke in the carotid territory and 
ipsiiateral severe carotid artery stenosis should be considered for carotid 
endarterectomy. Patients with infarction in watershed areas should be 
investigated for underlying causes of severe hypotension such as paroxysmal 
dysrhythmias or silent myocardial infarction. The aetiological subtypes of 
cerebral infarction are discussed in more detail below.
1.03 Brain embolism
Embolism has been identified as a frequent cause of brain infarction. Many 
potential sources of emboli are known, however it is often difficult to implicate
a particular embolic source following stroke as several potential predisposing 
factors may coexist within the same patient.
Cardiac embolism
Occlusion o f cerebral arteries arising as a result of embolus from the heart 
was recognised more than a century ago/® however until recently it was 
thought to be an uncommon cause of stroke. This view was revised when 
several large pathological studies suggested that cerebral embolism was the 
likely mechanism in approximately one quarter of all ischaemic strokes, with 
this proportion rising slightly in young patients with stroke. "
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Many cardiac problems can give rise to cerebral embolism. The commonest 
and most important disorder is atrial fibrillation (AF). Chronic AF of rheumatic 
or non-rheumatic origin is associated with a five *cld Irceased  risk of 
ischaemic stroke, independent of other factors such as age, sex and 
hypertension.’® Other disturbances of cardiac rhythm such as the sick sinus 
syndrome also significantly increase the risk of ischaemic stroke. These 
rhythm disturbances are common, particularly in the elderly population,’® and 
are easy to detect. Judicious use of anticoagulants in this group represents an 
effective means of primary stroke prevention.
In addition to disturbances of cardiac rhythm, structural cardiac disease may 
predispose to stroke. Left ventricular mural thrombus may arise as a result of 
recent myocardial infarction, left ventricular dilatation or left ventricular 
aneurysm. In autopsy series, left ventricular mural thrombus has been 
demonstrated in 20-60% of patients with myocardial infarction (Ml), although 
systemic embolisation is recognised in only 3-10% of post-Ml patients.
Paradoxical cerebral emboli may occur, usually through a patent foramen
ovale (PFO). Screening of asymptomatic individuals reveals that physiological 
shunting through a PFO may occur in 10-20% of those screened, however 
this proportion rises to 40-50% when young patients with stroke are studied. 
Cardiac valvular disease may lead to cardioemboiic stroke either as a result of 
valve-related rhythm disturbance or following thrombus formation on damaged 
native or prosthetic valves. Mitral valve prolapse (MVP) is the commonest 
form of adult valvular disease. Its significance in relation to cardiogenic
cerebral embolism remains unclear. It appears that the majority of patients 
with MVP are at no increased risk of ischaemic stroke unless there is 
associated e-ccthe!ia! damage or fibrinous deposits on tne affected valve.
A rte ry  “to-artery em bolism
Many sites on the arterial tree may give rise to emboli which occlude vessels 
distal to the source. Emboli arising in this fashion may be composed of fibrin / 
platelet aggregates, cholesterol crystals, calcified particles or other debris 
from ruptured atherosclerotic plaques, or red fibrin dependent thrombus. 
Identification of artery-to-artery embolism is difficult, hence its true frequency 
is difficult to estimate.’  ^ Embolic sources within both the intracranial and 
extracrania I portions of the internal carotid artery, the vertebral arteries, the 
basilar artery and the aortic arch have been reported.’ ^'’ ® ’®
The clinical characteristics of embolic brain infarction are variable; however a 
number of features are helpful in the identification of embolic disease. The 
abrupt onset of symptoms which do not fluctuate and can be attributed to 
superficial or cortical cerebral infarction is highly suggestive of an embolic 
mechanism. A history o f previous cerebral infarction in a different arterial 
territory, history of cardiac disease or abnormal findings on cardiac 
examination would all strengthen the suspicion of a central cardiac or arterial 
source.
Clinical suspicic" of an embolic aetiology should lead to an exhaustive search 
for a potential source. In addition to full neurological and cardiovascular
examination and brain imaging, electrocardiography (including prolonged 
monitoring), carotid ultrasound, echocardiography and cerebral angiography 
should be considered Tra-^s-oesophageal echocardiography should be 
considered in patients with normal trans-thoracic echocardiography in whom a 
suspicion of central embolism remains as this technique affords superior
'i-I
views of the left atrium, mitral valve, atrial septum and ascending aorta.
Therapeutic intervention will depend upon the results of these investigations.
.■ ;
Patients with cardiogenic embolism should be considered for systemic 
anticoagulation, while those with evidence of artery-to-artery embolism should 
be offered antiplatelet therapy and (if appropriate) surgical endarterectomy.
1.04 Large artery occlusive disease
The extracranial internal carotid artery supplies the ipsiiateral cerebral
hemisphere including most of the deep subcortical areas. Atherosclerosis 
involving this vessel most commonly affects the first 2 centimetres 
immediately distal to its origin. Atheroma at this site may lead to ischaemic 
stroke either due to artery-to-artery embolism or as a result of haemodynamic 
changes distal to the narrowed vessel, in the absence of adequate collateral 
circulation, complete occlusion of the internal carotid artery leads to extensive 
hemispheric infarction. When the vessel remains patent but is sufficiently 
narrowed to reduce cerebral perfusion, infarction of the “watershed” areas that 
lie at the boundaries of the territories of the major cerebral arteries may occur.
Watershed infarction may occur in the anterior border zone (between the 
anterior and middle cerebral arteries) or the posterior border zone (between
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The intracranial part of the internal carotid artery may also be affected by 
atheromatous change, particularly in the cavernous portion at the carotid 
siphon. As with more proximal disease of the internal carotid artery, ischaemic 
stroke may occur as a result of propagation of emboli from plaque at this site, 
or as a result of haemodynamic compromise distal to the narrowed vessel. 
The features of stroke arising as a result of intracranial internal carotid artery 
disease are indistinguishable from those due to extracranial disease. It is 
possible that the significance of intracranial carotid disease as a cause of 
stroke has been underestimated due to the inaccessibility of this portion of the 
artery to non-invasive investigation.^®
The middle cerebral artery is the larger of the two terminal branches of the 
internal carotid artery. This vessel supplies most of the lateral aspect of the 
hemisphere via its superior and inferior branches. It also supplies the basal 
ganglia and internal capsule through a number of small lenticulostriate end 
arteries which arise from the main stem. Infarction confined to the territory of 
the middle cerebral artery usually occurs as a result of cerebral embolism
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middle and posterior cerebral arteries). Anterior watershed infarction is 
characterised by crural or brachial paresis with relative sparing of the face. If 
the dominant ^e^dsphere 's .affected, transcortical motor aphasia may occur. 
Posterior watershed infarction presents with relatively little motor involvement, 
hemianopia or lower quadrantanopia, transcortical sensory aphasia and 
parietal lobe signs such as neglect in a non-dominant hemisphere lesion or 
dyscalculia if the dominant hemisphere is affected. i :
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from a proximal source, although atherosclerosis of the trunk of the vessel 
may occur and give rise to symptoms, particularly in Black and Asian 
popu la tions/’ Clinical features of -middle cerebral artery infarction cecend 
upon the site of the occlusion. Lesions proximal to the origin of the 
lenticulostriate arteries lead to extensive infarction involving cortical and 
subcortical regions of the affected hemisphere. The resulting clinical 
syndrome is characterised by dense hemiplegia in a pyramidal distribution, 
severe global dysphasia or neglect, hemianopia, hemisensory disturbance
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and conjugate eye deviation towards the side of the infarct. Neurological 
deficit imparted by more distal middle cerebral artery infarction is less severe 
and occurs in one of two patterns, depending upon which of the terminal 
branches is affected. Superior division infarction typically involves motor 
paresis and non-fluent language disorder with relative sparing of vision and 
sensation. Inferior division middle cerebral artery ischaemia is characterised 
by fluent language disorder with relatively little motor deficit.
The anterior cerebral artery is the smaller of the two terminal branches of the 
internal carotid artery. The artery runs forward from its origin, supplying the 
anterior and medial aspects of the hemisphere. Several deep branches run 
laterally to supply the anterior limb of the internal capsule and part of the head 
of the caudate nucleus. Infarction of the anterior cerebral artery is uncommon 
and usually due to embolism rather than intrinsic atherosclerosis. Clinical 
features of anterior cerebral artery occlusion comprise lower limb weakness, 
urinary incontinence and frontal lobe features such as abulia.
Î
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1The vertebral arteries, three sets of paired cerebellar arteries, basilar artery 
and posterior cerebral arteries together comprise the posterior circulation, 
which supplies brainstem, cerebellum, thalamus, occipital lobes and 
medial temporal lobes. Ischaemic damage to these regions may arise as a 
result of cerebral emboli or atheroma of the posterior circulation. As with the
'intracranial portion of the internal carotid artery, non-invasive demonstration of 
arterial disease in the posterior circulation is difficult without easy access to 
magnetic resonance angiography, hence the condition is under diagnosed 
and little is known of its natural history.®® The clinical features of posterior 
circulation ischaemia vary, depending upon the precise site of the lesion.
Basilar artery stenosis may present with recurrent stereotyped episodes of 
dizziness, dysarthria, hemi- or quadriparesis, diplopia or ataxia. In patients 
with thrombosis of the basilar artery, these symptoms may have a stuttering 
onset and may progress to coma.
Cerebellar infarction usually arises as a result of embolic occlusion of one of 
the cerebellar arteries, it is characterised by dysarthria, ataxia, nystagmus, 
vomiting and unsteady gait.®® Thalamic infarction, when unilateral, is manifest 
as dense hemisensory loss. Medial thalamic lesions may cause cognitive 
disturbance such as memory loss and agitation. Disturbance of sleep / wake 
cycle may also occur.®'’
Posterior cerebral artery infarction is usually embolic in nature and is manifest 
as isolated homonymous hemianopia as a result of unilateral occipital lobe
infarction, or as colour or visual agnosias which may occur when the medial 
aspect of the temporal lobe is involved.
Diagnosis of posterior circulation ischaemia has been greatly improved with 
the advent of magnetic resonance irr.aging (MRI). MR techniques are not 
limited by the bony artefact which greatly reduces the usefulness of 
conventional x-ray computed tomography in posterior fossa imaging. The 
superior spacial resolution of MR techniques allows identification of very small 
lesions, and magnetic resonance angiography provides a non-invasive means 
of imaging vessels not amenable to insonation.
1.06 Small artery occlusive disease
Small intracranial arteries arise from two main sources. Arteries arising from 
the large vessels at the base of the skull penetrate the substance of the brain
and supply the deep white matter of the cerebral hemispheres, the basal 
ganglia and the brainstem. A further group of small arteries originates from 
the pial arteries which lie in the subarachnoid space, closely related to the 
cerebral cortex. These penetrating arteries plunge from the hemispheric 
surface to supply subcortical regions of the hemispheres. Infarction of tissue 
supplied by these small arteries usually arises as a result of occlusion 
secondary to disorganisation of the vessel wall with disappearance of 
vascular smooth muscle, sclerosis, hyalinosis and lipid deposition. The main 
risk factor for this microangiopathy is hypertension. Following sustained, 
severe hypertension, fibrinoid necrosis, aneurysmal dilatation and intramumi 
haemorrhage may occur in addition to the lipohyaiinosis described above.
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Occlusion of these small arteries leads to lacunar infarction:®® small, well 
defined areas of cerebral infarction involving the deep white matter of the 
hemispheres the basa' ganglia or brainstem. The clinica Matures of lacunar 
infarction are well recognised. Pure motor stroke arises as a result of lacunar 
infarction involving the corticospinal tract either in the corona radiata, internal 
capsule, mesencephalon, pons or medulla. Typically the face and limbs are 
equally affected; the deficit is not associated with other neurological 
symptoms and in 16-57% of patients may have been preceded by similar, 
transient symptoms.®®
Lacunar infarction may affect the sensory pathways alone, causing pure 
sensory symptoms, or may involve both sensory and motor pathways as they 
run in apposition in the corona radiata, thalamocapsular area, pons or 
medulla. Less commonly encountered are the syndromes of ataxic 
hemiparesis and dysarthria / clumsy hand. Interruption of the cerebello- 
thalamo-cortico-ponto-cerebellar loop by a lacunar lesion in the corona 
radiata, internal capsule or pons has been proposed as the underlying 
mechanism.®’'
Isolated lacunar infarction causes well-recognised lateralised symptoms, 
however multiple events may lead to more diffuse symptoms, culminating in 
the “état lacunaire”, characterised by the progressive development of 
abnormal gait (“marche à petits pas") incontinence, dysarthria and cognitive 
impairment. Only a minority of patients with lacunar stroke will progress to the
état lacunaire. The prognosis following lacunar infarction is better than for 
other stroke subtypes, with 5-10% mortality at one year.®®
1.06 Stroke and hypertension
High b'ood pressure is the single most important risk factor for the 
development of cerebrovascular disease. In one report,®^ 70% of all patients 
presenting with acute ischaemic stroke were found to be hypertensive, and a 
history of chronic hypertension was obtained from approximately half of these 
patients. The role of antihypertensive treatment in primary prevention of 
stroke is well established. Meta-analysis"' of a number of large prospective 
studies has shown that a reduction in diastolic blood pressure of 5 mmHg 
confers a 42% reduction in stroke risk. The relationship between blood 
pressure and incidence of stroke appears to be log-linear,®’ with no apparent 
threshold level below which no further reduction in stroke risk accrues. It has 
been suggested that this relationship may be even stronger than initially 
suggested due to sampling error, as the baseline blood pressure values took 
no account of random blood pressure fluctuation and errors inherent in blood 
pressure measurement. This phenomenon, termed “regression dilution bias”®® 
results in underestimation of the strength of the relationship between blood 
pressure and stroke. It has been estimated that correction for regression 
dilution bias increases the gradient of the relationship by 60%.®®
The benefits of antihypertensive therapy in patients with established 
cerebrovascular disease are less well established. Although a similar log- 
linear relationship between blood pressure and recurrent stroke incidence has
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been reported,®'’ other studies have postulated a J-shaped curve with 
progressive increase in the risk of stroke recurrence as diastolic blood 
pressure falls below 80 mmHg.®® As a similar relationship has been 
demonstrated between blood pressure and myocardial infarction,®® it has 
been suggested that patients with pathologically low blood pressures due to 
cardiac disease are responsible for the observed increase in vascular events 
as blood pressure falls.®^
Cerebral autoregulation
Hypertension accelerates and contributes to many of the pathophysiological 
changes in the heart, intracranial and extracranial vasculature which 
predispose to the development of both ischaemic and haemorrhagic stroke. 
The mechanisms through which large vessel atheroma, arteriosclerosis, 
lipohyaiinosis of small intracerebral vessels or coronary artery disease may 
cause stroke have been discussed; however in the hypertensive brain 
changes in cerebral autoregulation may confer additional risk o f cerebral 
ischaemia. Under normal circumstances, the normotensive individual is able 
to regulate cerebral perfusion over a broad range of blood pressure. Cerebral 
blood flow remains constant at approximately 50 millilitres of blood per 100 
grams of brain tissue per minute provided that mean arterial blood pressure 
remains between approximately GO mmHg and 140 mmHg. In chronically 
hypertensive individuals, the autoregulatory mechanism becomes “reset” at a 
higher level of blood pressure. This confers the ability to withstand higher 
levels of blood pressure without the development of cerebral oedema, 
however the individual becomes less able to maintain cerebral perfusion when
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a hypotensive episode occurs. This cerebral hypoperfusion is manifest 
clinically as watershed cerebral infarction in a hypertensive patient, occurring 
at relative /  "normal” levels of blood pressure. Cerebral autoregulation has 
been extensively studied in animals. Normalisation of cerebral autoregulation 
has been oemonstrated in hypertensive animals treated with antihypertensive 
therapy;®® to date experiments in humans have failed to demonstrate similar 
findings.""
Primary prevention of stroke
Meta-analysis of prospective blood pressure lowering studies®’ in patients 
without pre-existing cerebrovascular disease suggests that considerable 
reduction in stroke risk is achievable with only modest blood pressure 
reduction. The proportional reduction in stroke risk seen in blood pressure 
trials with lower blood pressure criteria was comparable to the reduction in
stroke risk seen in trials with higher blood pressure criteria. In terms of 
primary prevention of stroke, similar benefit is derived from treating all 
patients with relatively mild hypertension as is derived from treating a cohort 
of more severely affected individuals.
Assuming the group risk reductions seen in this meta-analysis are applicable 
to individuals, it would appear that the highest ratio of strokes prevented to 
patients treated will be seen in patients at highest risk. Risk of stroke 
increases with age: middle-aged hypertensives have an annual stroke risk of 
0.5%.®® whereas in the hypertensive elderly population this risk is trebled.^®
i
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Extrapolation from the conclusions of the meta-analysis,®’ over a treatment 
period of 10 years, the number needed to treat to prevent one stroke in the
hypertensive elderly population would be 17, compared to 50 in the 
hypertensive middle-aged population.
Primary prevention of stroke in the elderly
The potential benefit of intervention to lower blood pressure in the 
hypertensive elderly population has been demonstrated in a number of large 
prospective studies. Reductions in vascular death and non-fataI coronary and 
cerebrovascular events have been reported in patients over 60 years of age 
with isolated systolic hypertension.'”  In this study, relative reduction in stroke 
risk was 36% indicating that in the elderly population treatment of isolated 
systolic hypertension confers benefit.
The epidemiological evidence linking hypertension to stroke recurrence is less 
clear than that linking hypertension to first stroke. Retrospective analysis o f a 
large cohort of patients over a 30 year period failed to demonstrate a 
significant relationship between stroke recurrence and level of blood 
pressure.'’  ^ A smaller prospective study of blood pressure reduction in 
normotensives following TIA or non-disabling ischaemic stroke demonstrated 
a direct and continuous relationship between blood pressure and the 
secondary incidence of stroke.'’® This and three other studies®’ '^ '’ examined 
the effect of intervention to lower blood pressure on risk of stroke recurrence 
in normotensives or hypertensives. Due to a combination of small numbers of 
participants and modest blood pressure reduction in the treated groups, all
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four studies were inconclusive. Meta-analysis of these studies suggests
reduction of stroke risk of 19%, but with wide confidence intervals (95% C I -  
4 9%. + 1^%)
More definitive evidence of the effect of blood pressure lowering on risk of 
stroke recurrence is expected when the perindopril protection against
recurrent stroke study (PROGRESS)'’® reports in 2001. This study has 
recruited 6000 normotensive or mildly hypertensive stroke survivors and is 
following them up over five years. It aims to investigate the efficacy of a 
thiazide diuretic and / or an angiotensin converting enzyme inhibitor as 
secondary prevention of stroke in this population. Although the reduction in 
blood pressure achieved in the treated group is rather lower than initially *
predicted (12.1 / 4.8 mmHg in the dual therapy cohort), the event rate is 
higher than expected and thus the PROGRESS study should be adequately 
powered to assess the benefit of blood pressure lowering treatment in 
patients with cerebrovascular disease.
Blood pressure lowering acutely after stroke
There are a number of theoretical reasons why intervention to lower elevated 
blood pressure in the context of acute ischaemic stroke may have a 
deleterious effect. It is known that focal impairment of cerebral autoregulation 
may occur in the acute phase after stroke.'’® In the affected area, reduction in 
cerebral perfusion pressure may not be met with reflex arterial vasodilatation, 
resulting in cerebral hypoperfusion. This further ischaemic insult may increase 
cerebral damage and worsen outcome. A further potential hazard of blood
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pressure lowering in acute stroke is the risk of reducing pressure across an 
undiagnosed stenotic lesion involving a large extra- or intracranial artery.
Some evidence from prospective studies supports the theoret cal concerns 
described above. The INWEST'’ *' study of intravenous nimodipine infusion 
after acute stroke demonstrated an association between early fall in blood 
pressure and worse clinical outcome. In a small pilot study of the ton channel 
blocker Lifahzine'’® a fall in blood pressure was associated with poor outcome 
in elderly female recipients of the drug. It should be emphasised that the 
deleterious effect of blood pressure lowering early following stroke does not 
apply to patients with severe or accelerated-phase hypertension. In these 
patients very high levels of blood pressure are associated with headache, 
seizure activity and focal neurological disturbance. Intervention to lower blood 
pressure over a matter of hours should be instituted to prevent worsening of 
cerebral oedema and to reduce the risk of potentially fatal hypertensive 
complications. Cautious intervention to lower blood pressure may also be 
warranted in stroke patients with co-existing illness such as severe cardiac 
failure, dissecting arterial aneurysm or acute myocardial infarction.
Blood pressure management following stroke is further confounded by 
physiological blood pressure changes which occur in patients admitted to 
hospital with stroke. An initial blood pressure rise and subsequent fall over 48- 
72 hours is well recognised."' This fluctuation appears to be related to 
psychosocial and physical stress associated with hospital admission, hence is 
not indicative of antecedent hypertension. Decisions regarding long term 
blood pressure treatment should therefore be deferred until a consistent
. J'
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series of blood pressure readings have been obtained and evidence of pre- 
existing hypertension such as left ventricular hypertrophy on ECG or evidence 
of end organ hypertensive damage has been sc^ghi. The observed 
fluctuation in blood pressure tends to be more pronounced in patients with 
intracranial haemorrhage/® and as elevated blood pressure in these patients 
may predispose to further intracerebral bleeding, a more aggressive approach 
to the treatment of elevated blood pressure is probably justified although little 
prospective evidence is available.
There is relatively little published evidence to guide clinicians in their choice of 
antihypertensive agent in both acute and long term intervention to lower blood 
pressure after stroke. In the rare situations where urgent early intervention to 
lower blood pressure is required, the choice of agent may be restricted due to 
swallowing difficulty or other coexisting conditions such as severe heart 
failure. If parenteral therapy is necessary, short acting agents such as nitrates 
should be infused as this obviates any risk of prolonged and precipitous fall in 
blood pressure.
Due to the paucity of prospective evidence concerning secondary 
preventative blood pressure treatment, the choice of antihypertensive agent is 
usually determined by co-existing conditions and by the preference of the 
clinician. There is some evidence to suggest that, unlike older 
antihypertensive drugs, angiotensin converting enzyme inhibitors can reduce 
blood pressure without lowering cerebral blood flovT' in patients with 
cerebrovascular disease. These agents have also been shown to reduce the
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incidence of recurrent myocardial infarction in h u m a n s . a n d  cause 
regression of atheromatous plaque primates.
It is clear that intervention to reduce elevated blood pressure reduces risk of 
first stroke, and evidence is emerg.ng that risk of stroke recurrence can be 
reduced with satisfactory blood pressure control. The optimal management of 
blood pressure acutely after stroke or in normotensive stroke survivors 
remains unclear. Further research is required in order to define which patients 
to treat, when to institute therapy ana which agents to use.
1.07 Blood glucose after stroke
The significance of blood glucose concentration in the context of experimental 
neuronal ischaemia has long been appreciated. The role of hypergiycaemia in 
patients with acute stroke is less well defined. Animal work suggests that the
detrimental effects of hypergiycaemia are mediated by a number of 
mechanisms and vary depending on the site and extent of cerebral ischaemic 
insult. There is some early evidence from clinical trials to suggest that 
observations in the animal model may be involved in human stroke. Published 
evidence of the effects of hypergiycaemia in both the animal model and 
humans will be briefly reviewed
Focal cerebral ischaemia
In the experimental model, hypergiycaemia during focal cerebral ischaemia 
exerts a variety of effects on infarct size, tissue pH and functional outcome. 
Investigation of the influence of serum glucose concentration on infarct size
following permanent feline MCA occlusion by de Courten-Meyers revealed 
significant increases in infarct size and mortality affecting animals rendered 
hyperglycaemic wif^ IV infusion of 1GA3 dextmse cr.c" to onset of ischaemia. 
Similar increases in infarct size were observed m hyperglycaemic rats (blood 
glucose 119-360 mg/dl) following thread occlusion of the MCA.^^ The authors 
of both of these studies concluded that serum glucose concentration at the 
time of large cerebral vessel occlusion influences stroke outcome. Chemical 
analysis of ischaemic neuronal tissue in monkeys has suggested that 
hypergiycaemia reduces pH of affected brain, possibly due to local 
accumulation of lactic acid.^® Tissue acidosis has also been observed in the 
rat model of hyperglycaemic cerebral ischaemia and in addition, significantly 
elevated levels of cortical lactate have been consistently noted in 
hyperglycaemic a n i m a l s . T h i s  finding has been attributed to a relatively 
greater availability of substrate for anaerobic glycolysis within the ischaemic 
brain tissue of these animals. As lactic acid is thought to be a significant 
mediator in the final common pathway of ischaemic cell death (possibly due to 
promotion of free-radical formation), the authors postulated that increased 
glucose delivery to the ischaemic penumbra was the most likely mechanism 
for their observations.
The picture is somewhat clouded by the failure attempts to reproduce the 
findings of de Courten-Meyers’ g r o u p . Z a s s i o w  et al suggested that 
hypergiycaemia decreased the extent and severity of acute neuronal 
ischaemic changes in the cat model of permanent MCA occlusion, The 
discrepancy between these two cat studies may in part be explained by minor
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methodological differences (survival times of six hours^"' compared with two 
weeks®®) and by relative differences in blood glucose concentration of 33%. 
Similar discrepancies were foimd when the studies in rats were repeated.®' 
These differences were found not to be attributable to methodological 
differences and led to further, more detailed study of other factors which may 
have influenced outcome. It was found that hypergiycaemia adversely affects 
outcome in models of focal thrombotic infarction when the affected tissue 
receives collateral supply, Hypergiycaemia prior to and during infarction 
involving non-anastomosing arterial beds does not increase and may reduce 
the eventual infarct volume.®®
The protective effect of hypergiycaemia following end-arterial infarction may 
possibly be explained by the stabilising effect it has on the membranes of 
neurones in the peri-infarct region. High levels of blood glucose prevent the 
spontaneous potassium depolarisation usually observed in the peri-infarct 
neurones of normoglycaemic animals.®® This in turn prevents the acceleration 
in cellular metabolism that has been associated with selective neuronal death 
seen in the normoglycaemic model,
Hypergiycaemia following human stroke
The effect of hypergiycaemia upon outcome following human stroke has been 
the subject of much interest, however, as in the experimental model, 
conflicting results have frequently been reported. Retrospective studies in 
America have revealed relatively coorer neurologic outcome following stroke 
in patients with diabetes.®^ In later studies of non-diabetic stroke patients,®® an
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association between hypergiycaemia at presentation, larger infarct volume (as 
assessed by CT) and poorer neurological outcome was observed. Other 
authors have noted an apparent association between ra sed blood glucose 
and incidence of cerebral oedema following stroke, independent of the 
presence of pre-existing diabetes.®'*
Studies of cerebral metabolism immediately following stroke using positron 
emission tomography®® have revealed an association between 
hypergiycaemia and altered regional glucose metabolism within the brain, 
including lower glucose consumption within the ischaemic area, and 
asymmetries in glucose consumption when homologous areas of each 
hemisphere are studied. The significance of these findings has yet to be 
established.
There has been much debate over the interpretation of the results of these 
clinical studies. The elevated levels o f blood glucose may have caused the 
larger infarcts and hence worsened outcome or may simply reflect a greater 
stress response as result of a relatively larger ischaemic insult. In an attempt 
to clarify whether the relationship between elevated blood glucose and poor 
outcome was one of cause or effect, a number of studies attempted to 
measure other markers of the physiological "stress response" in the context of 
acute cerebral ischaemia. Myers et al®® reported abnormally high levels of 
sympathetic activity in patients with cerebral infarction. The degree of 
activation of the “stress response” was assessed by analysing plasma levels 
of noradrenaline, adrenaline and dopamine. Levels of these hormones were
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s gnificantly elevated in patients with cerebral infarction compared to control 
subjects. Patients with transient ischaemic attack had intermediate levels of 
c ’asma catecholamines. The investigators fo u r :  no correlation be:v/een 
catecholamine level and stroke severity, type or location, nor did the 
G Terences correlate with age, blood pressure or heart rate. Other studies 
have revealed significant activation of the cortisol axis following stroke. Higher 
levels of urinary cortisol excretion were found in patients with acute stroke 
than control subjects. The degree of activation of the cortisol axis correlated 
v.'th elevation of plasma catecholamine levels. High cortisol excretion was 
also significantly associated with poorer functional outcome in a discriminant 
analysis. Significantly, these and other®® studies did not show an association 
between plasma catecholamine levels or urinary cortisol and blood glucose 
concentration, irrespective of the presence or absence of diabetes. The 
authors concluded that hypergiycaemia observed during the acute phase of 
stroke cannot be explained by increased stress.
This finding has been substantiated by a recent long term follow up study.^® 
The effect of hypergiycaemia on stroke mortality and morbidity was studied by 
assessing its effect on outcome after adjusting for known prognostic factors. 
Plasma glucose concentration above 8 mmol/lit predicted poor prognosis after 
correcting for age, stroke severity and stroke subtype The authors concluded 
thai raised plasma glucose is unlikely to be due to a stress response and 
should arguably be treated actively. Randomised, prospective trials to 
examine the effect of intervention to lower blood glucose in hyperglycaemic 
stroke patients are needed.
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Global cerebral ischaemia
Animal models of globs' cerebmi ischaemia (induced card s : arrest, artificial 
hypotension, bilateral carotid occlusion) have demonstrated that acute 
hypergiycaemia prior to global cerebral ischaemia worsens neurologic 
dam age/^ impairs recovery of ATP/® and causes greater delayed 
hypoperfusion/" These findings have been observed in both rats and 
primates, and are consistently affected by the timing and duration of 
hypergiycaemia relative to the ischaemic insult. The most deleterious effects 
were seen when glucose was administered prior to onset of global ischaemia. 
This significant increase in cerebral injury was observed even when blood
glucose had fallen to physiological levels at the time of induction of cerebral 
ischaemia.
Although these experimental findings have been largely reproducible, other 
published work^'* has observed differences in cortical lactate concentrations 
between hyper- and normoglycaemic rat models of global ischaemia with no 
associated difference in infarct size or functional outcome. .Although the 
methodology of this study has been criticised,^® the findings remain 
unexplained.
Glucose handling in the immature brain is known to differ from adult brain. 
Unsurprisingly, the effect of elevated glucose concentration on Ischaemic 
brain injury has been shown to differ in immature animals.^® Hyperglycaemic 
ischaemia in the young rat is associated with neither cortical lactate
accumulation nor alteration of whole-bra n glucose metabolism. It has been 
postulated^^ that the anaerobic threshold is higher in immature brain tissue, 
hence the role of glucose in the generat : - of lactate is diminished.
Relat vely few studies of hyperglycaeme in the context of global cerebral 
ischaemia exist, and the results are inconclusive. Premorbid hypergiycaemia 
may correlate with poorer neurologic recovery post arrest but the evidence is 
not compelling. Blood glucose measurements taken during cardiopulmonary 
resuscitation tend to be too closely related to the duration and difficulty of 
resuscitation to provide useful information on the effect of peri-arrest 
hypergiycaemia on neurologic recovery.
Glucose, diabetes and stroke
Patients with diabetes are at greater risk of stroke than the non-diabetic
population. Following stroke, the prognosis for patients with diabetes is known 
to be poorer, and their recurrence risk is higher/® There are many potential 
reasons for these observations, and the relative significance of each is 
unclear. Patients with diabetes have a three-fold increase in the frequency of 
proliferative lesions characterised by basement membrane thickening and 
endothelial cell proliferation. An increased prevalence of extracranial carotid 
atherosclerosis is found within the diabetic population and other peripheral 
vascular disease is more common. In addition to vascular factors, other 
contributory factors to the increased incidence of stroke have been 
postulated. The erythrocytes of diabetic oatients are less deformable and
blood viscosity tends to be more variable/® These factors may be implicated 
in the development of small-vessel cerebral infarction.
Studies in humans have suggested that chronic hypergiycaemia is associated 
with alteration of cerebral haemodynamics, specifically reduced MCA 
velocities and some loss of cerebral autoregulatory function/® Glucose 
handling within the brains of diabetics differs from that of non-diabetic 
individuals. The precise nature of the metabolic abnormality has yet to be 
identified; however it is known that neuronal glucose uptake in diabetic 
patients is similar to non-diabetics, and it is assumed that the observed 
differences in glucose metabolism are due to altered intracellular processes.
Similar abnormalities of intracranial haemodynamics have been observed in
and preservation®® of cerebral autoregulatory mechanisms have been 
reported.
The observed differences between the findings of human and animal studies 
may relate to the imperfect nature of the animal model of diabetes. It is 
apparent that the effects of chronic diabetes on the cerebrovascular system 
are many and complex, and are dependent upon a host of other factors such
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animal models of chronic hypergiycaemia/^ however these findings are less
#!'
consistent than published human data, and some authors have reported 
increased cerebral blood flow in the chronically hyperglycaemic rat.®'' 
Discrepancies are also found when studies of cerebral autoregulation and
brain glucose metabolism In diabetic animals are examined. Relative failure®^
Comparison of hypo- and hyperglycaemic animals in experimental models of 
cerebral ischaemia has revealed higher intracellular pH, more favourable
as age. blood pressure, lipid status and cigarette consumption. Further 
research into this area is underway.
Intervention with insulin during cerebral ischaemia
As mentioned above, little is known of the effect of insulin upon outcome in 
hyperglycaemic patients with ischaemic stroke. Theoretically, intervention to 
lower blood glucose in ischaemic stroke should reduce the supply of substrate 
for anaerobic glycolysis within penumbral brain tissue, hence reducing 
neuronal death and improving eventual outcome. In addition to its 
hypoglycaemic effect, it has been suggested that insulin may act centrally at 
insulin-like growth factor receptors expressed within the CNS, exerting a 
neuromodulatory effect. This postulated neuroprotective effect independent of 
hypoglycaemic action is under investigation and some supportive evidence 
has been published®'^ however the effect is thought unlikely to achieve clinical 
significance. In addition to its local effects following focal cerebral ischaemia, 
insulin may exert some beneficial systemic and haemodynamic effects.
■ 1
Intense insulin treatment may affect platelet function, correct disturbed 
lipoprotein patterns®® and decrease plasma activity of plasminogen activator 
inhibitor,®^ which has been shown to be elevated in diabetic individuals. When 
considering the potential benefit of insulin administration, it is important to be 
aware of the detrimental effects of excessive hypoglycaemia on the brain.
These are described elsewhere.®®
’:S
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cellular energy state and lower intracellular lactate levels in hypoglycaemic 
animals/®
Comparative studies observing the effects of pre-ischaemic glucose
manipulation provide conclusive evidence of the beneficial effect of mild
hypoglycaemia immediately prior to the ischaemic insult. Of more clinical 
relevance are the studies examining the potential benefit of glycaemic 
manipulation following ischaemia. in the rat model, intervention with insulin to
reduce elevated levels of blood sugar to euglycaemic levels following the
induction of ischaemia has been shown to reduce consequent cerebral 
ischaemic damage, improve functional outcome and effectively negate the 
detrimental effect of pre-ischaemic hypergiycaemia.®® As expected, excessive
on neuronal tissue may depend upon the degree of collateral blood supply to 
the affected area. Although there is a paucity of prospective data at present, 
current evidence suggests that intervention to reduce high levels of blood
i
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postischaemic hypoglycaemia in the animal model is associated with 
increased seizure activity and poorer outcome.
T
Summary
The relationship between hypergiycaemia and outcome following cerebral 
ischaemia is not yet fully understood. There is reasonable evidence to 
suggest that hypergiycaemia immediately following cerebral ischaemia is not 
entirely attributable to a stress response and that it predicts a relatively poor 
prognosis. Experimental data would suggest that the effect of hypergiycaemia
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sugar while avoiding hypoglycaemia is justified until prospective data to guide 
clinicians become available.
1.08 Imaging of acute ischaemic stroke with x-ray computed 
tomography.
As discussed above, the diagnosis of acute stroke is based upon clinical 
observation and exclusion of other potential causes of focal neurological 
deficit such as seizure activity or metabolic disturbance. Unequivocal 
confirmation of the diagnosis and precise lesion localisation often require 
imaging with x-ray computed tomography or magnetic resonance scanning. At 
present, CT scanning is performed more commonly than MR scanning in 
patients with acute ischaemic stroke. Although magnetic resonance 
techniques are known to be more sensitive and specific than CT imaging in 
the context of cerebral ischaemia, CT is more widely available and can 
reliably exclude haemorrhage or tumour. Computed tomography of the brain 
is performed in the axial plane. A rotating x-ray tube projects a collimated 
beam of x-rays through the head parallel to the plane joining the lateral 
canthus to the external auditory meatus. The beam is attenuated to a variable 
extent, depending upon the density of the materials through which it passes. 
Beam attenuation is measured using a detector, and the information is 
processed by computer to generate an image of the brain in the transaxial 
plane. Images are usually acquired at 5 millimetre intervals through the 
posterior fossa and at 10 millimetre intervals through the cerebral 
hemispheres although these intervals may be changed for certain 
applications.
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In the first hours following ischaemic stroke, the pathophysiological processes 
which characterise acute ischaemic injury do not change the electron density 
of the affected tissue, hence during this time up to 60% of CT scans are 
normal.®' Early changes in CT appearances after stroke are subtle and may 
be easily missed by the inexperienced. Parenchyma! changes reported on CT 
imaging in the acute phase of stroke include mild sulcal effacement, blurring 
of the internal capsule, loss of the insular “ribbon" and of grey / white matter 
discrim ination at the boundary of cortex and subcortex.®' Following 
ischaemic stroke in middle cerebral artery territory, the “Dense MCA" sign 
occurs with a reported frequency of 35-50%.®® The hyperintensity of the 
proximal part of the middle cerebral artery is thought to represent lodged 
embolus or thrombus in this vessel. Similar appearances may be seen in the 
posterior fossa following basilar artery occlusion. Although a useful indicator 
o f ischaemic middle cerebral artery stroke or basilar thrombosis in patients 
with no parenchymal change on CT, non-occlusive chronic calcification of 
atheromatous deposits in the middle cerebral or basilar artery can give rise to 
sim ilar appearances.®®
1.09 Basic principles of magnetic resonance imaging
Magnetic resonance imaging (MRl) is a technique which provides high quality 
images of structures within the human body, it is based upon the principles of 
nuclear magnetic resonance, and was developed from techniques used by 
scientists to obtain information about the physical and chemical properties of 
molecules. The first successful experiments with nuclear magnetic resonance
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were performed in 1946 by Bloch and Purcell. Their work led to the 
development of NMR spectroscopy as a powerful analytical tool in chemistry
and biology The potential of NMR to obtain images the intact human body 
was recognised approximately thirty years later,
MRl was initially able only to provide tomographic images; however as the 
technique was further developed, more complex functional and volumetric 
studies became possible and the clinical utility of MRl became apparent. The 
technique has a wide range of clinical applications, and is increasingly used 
by clinicians from many specialities.
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Magnetic resonance physics
The physical principles which underlie magnetic resonance imaging are 
complex. Images are generated by detection of signals emanating from the
hydrogen nuclei which abound within the human body. The nucleus of a 
hydrogen atom comprises a single proton. This proton possesses a 
fundamental property o f nature called spin, which causes it to behave like a 
very small magnet with a north and a south pole. When the proton is placed in 
an external magnetic field, it aligns itself along the field in one of two possible 
configurations, which possess differing energy states (figure 1.1). When the 
poles of the protons are aligned north-south south-north (N-S S-N) relative to 
the magnetic field, the energy state is low, and when the configuration is N-N 
S-S the energy state is high.
II
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F igu re  1.1 -  Proton alignment in external magnetic field
Bo represents external magnetic field, Mo represents net magnetisation vector.
A n iip o rd ie l — high energy
Pcinallel — low energy
A proton in a magnetic field can move from low to high energy states by 
absorbing a photon. In order that this occurs, the photon must possess 
exactly the same amount of energy as the energy d ference between the two 
states. The energy of a photon (E) can be calculated by the equation
E = hy
where v is the frequency of the photon and h is Plank’s constant (h = 6.624 x 
10'^'*). In MRl, V is called the resonance frequency or the Larmor frequency 
and lies within the radiofrequency range (15-80 MHz).
On a macroscopic scale, the sum of all of the magnetic fields generated by 
protons within an externally applied magnetic field can be considered. This 
net magnetic vector is proportional to (N^-N ) where N’*' represents the total 
number of protons in a high energy configuration and N' represents those in a 
low energy configuration (figure 1.2).
At equilibrium, the position of the net magnetisation vector lies along the 
direction of the applied magnetic field and is called the equilibrium 
magnetisation Mq. It is possible to change the net magnetisation vector by 
exposing the nuclear spin system to energy of a frequency equal to the 
energy difference between the spin states. If enough energy is put into the 
system, it is possible to saturate it and maximise the net magnetisation vector. 
Once the exposure to external energy has ceased, the system returns to 
equilibrium. The time constant that governs the return to equilibrium is called 
the spin lattice relaxation time (Ti). The equation governing this behaviour as 
a function of the time (t) after displacement is
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Figure 1.2 - Net magnetisation vector
Each circle represents one proton aligned in the magnetic field in one of the 
t.vo possible configurations. The net magnetisation vector for one of the six 
:  ccks of protons shown is represented by an arrow
enr
M2=Mo(1-e*^’)
where Mz represents the degree of displacement from the equilibrium position
(figure 1 3 '
in addition to displacement along the axis of the externally-applied magnetic 
field, the protons may be displaced In the plane perpendicular to the magnetic 
field. This is called transverse magnetisation. As with displacement along the 
axis of the magnetic field, the degree of displacement rapidly returns to the 
equilibrium value, giving off radiofrequency energy as it does so. The time 
constant which describes this behaviour is called the spin-spin relaxation time, 
T2. The spin-spin relaxation time is always less than the spin-lattice relaxation 
time. It is calculated using the formula
M xy“ WIxyo© ^ ^
Where Mxy is the magnitude of the displacement in the plane perpendicular to
the magnetic field (figure 1.4).
In summary, the spin-spin relaxation time (T2) is the time taken to reduce the 
transverse magnetisation by a factor of e. The spin lattice (Ti) relaxation time 
is the time taken to reduce the longitudinal magnetisation by a factor of e. The 
energy released by the protons as they return to the equilibrium position is 
recorded as an electrical signal which is subsequently processed and an 
image is generated.
By altering the parameters of the magnetic field gradients and radiofrequency 
pulses, images can be preferentially sensitised to particular structures and
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Figure 1.3 -  Relationship of spin lattice relaxation time (T1) to net 
magnetisation vector.
Figure 1.4 -  Relation of spin-spin relaxation time (T2) to transverse 
magnetisation.
:
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"processes within the body. More detailed discussion of the physical principles 
of magnetic resonance is outwith the scope of this introduction.
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Magnetic resonance imaging of ischaemic stroke
In the context of acute cerebral ischaemia, magnetic resonance imaging holds
.
a number of advantages over other radiological modalities and is rapidly 
becoming the investigation of choice in patients with stroke. The main goals of 
neuroimaging in acute stroke have been
• To confirm a vascular cause of neurologic dysfunction.
• To provide radiological evidence of tissue ischaemia and define the 
vascular territories involved.
• To exclude haemorrhage or haematoma in anticipation of thrombolytic 
treatment.
Using techniques discussed later. MRl is capable of achieving these goals at
an earlier stage in the natural history of a stroke event than other imaging 
modalities. Lesions in areas poorly - seen using CT or SPECT are more easily | |
visualised on MRl due to greater anatomical detail and reduced artefact. The 
ability to diagnose and classify stroke early in the course of the illness allows 
the provision of early and appropriate thrombolytic therapy, may assist in the 
development and assessment of neuroprotective agents and will assume an 
increasingly important role as novel therapies for acute stroke enter clinical 
practice.
Although magnetic resonance imaging has a number of distinct advantages 
over other techniques, certain practical considerations limit its applicability. As I
the generation of an image requires the application of strong magnetic 
gradients, metallic implants such as permanent pacemakers or foreign bodies 
represent an absolute ::-tra ind ica tion  to magnetic resonance imaging. As 
most magnetic resonance imaging examinations involve placing the patient in 
a confined and noisy environment, patients with claustrophobia or anxiety 
disorders are frequently unable to tolerate the scanning process. Many 
magnetic resonance sequences are exquisitely sensitive to patient movement 
and require adequate patient co-operation for the generation of ciinically- 
useful images. Acutely-ill patients such as those with ischaemic stroke may be 
too restless or too agitated to undergo magnetic resonance scanning. 
Approximately one quarter to one third of all stroke patients referred for MR 
investigation are unable to be scanned for these reasons.
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Detection of cerebral ischaemia by magnetic resonance depends upon the 
evaluation of four features.
•  Vascular flow abnormalities.
•  Mass effect.
• Parenchymal signal characteristics,
•  Parenchymal enhancement by contrast material.
%
A ssessm en t o f vascu la r flow  abnorm a lities  using magnetic resonance 
Cerebral ischaemia develops when cerebral blood flow drops from its normal
level o f approximately 55 mi/100g/min to 20-25 ml/100g/min. Normal flow
through cerebral arteries is seen on MR images as an area of greatly reduced 
signal intensity within the umen of the artery (the flow void phenomenon).
When flow through an artery slows or the artery is occluded, this flow void 
disappears. On Ti weighted images the flow void is replaced by an area of 
iso- or hyperintense signal with respect to surrounding brain parenchyma.
Vascular flow abnormalities can be more easily seen when contrast media are 
administered. The arterial enhancement seen in areas of compromised blood 
flow is likely to be a manifestation of low velocity flow associated with vascular 
stenosis, occlusion or mass effect from cerebral swelling.
A more specific means of imaging the cerebral vasculature is magnetic 
resonance angiography. This technique provides detailed images of the 
arteries and veins without the need for the introduction of contrast agents.
There are two general types of MRA ‘
• Time of flight angiography.
•  Phase contrast angiography.
Time of flight angiography uses slice selective 90 degree and 180 degree 
pulses. These pulses cause proton spin in opposing directions. In the 
absence of flow, no signal is seen as no protons experience both the 90 and 
180-degree pulses. In the presence of flow, blood from the 90-degree plane 
flows into the 180-degree plane and an echo is produced from which an 
image is generated.
Phase contrast angiography is more complex. This method uses alternating 
bipolar pulses to impart spin first in one direction then the other. Stationary
protons experience no net effect frc ^  this process as the opposite spins 
negate each other. Moving protons (i.e. those within flowing blood) experience
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an additive effect from sequential pulses and give off a radiofrequency signal
which is converted into an image.
1
Parenchyma! signal changes
The remaining three factors which affect the detection of cerebral ischaemia 
by magnetic resonance are biological processes which take longer to develop 
and may not be apparent using conventional MR in the hyperacute phase of
.1
stroke. Parenchymal signal change and mass effect arise as a result of 
degradation of the blood - brain barrier, changes in tissue water content and 
loss of autoregulation.
Critically-ischaemic cerebral tissue experiences metabolic and cell-membrane 
dysfunction within the first few hours of the onset of ischaemia. This results in 
the accumulation of intracellular water, sodium, lactate and calcium with
subsequent swelling of the affected area - a phenomenon termed cytotoxic 
oedema. This process is not well seen using conventional T2 weighted 
techniques and may resolve if normal perfusion is restored. Should ischaemia 
continue for six hours or more, a predominantly extracellular accumulation of 
water occurs which has been attributed to shift of macromolecules and water 
into the interstitium following breakdown of the blood brain barrier. This 
process, termed vasogenic oedema, may be visualised on conventional T2 
MRl sequences as an area of high signal. The radiologic change may not be 
visible until eight hours post onset of ischaemia.
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It is clear that conventional T i, T 2 and proton density images cannot be relied 
upon to demonstrate cerebral lesions until at least six hours after the 
ischaemic -suit Magnetic resonance angiogmchy re.eais occlusive lesions 
in large vessels acutely; however this technique is technically demanding, 
yields no information on brain parenchyma and the long acquisition time 
required to obtain a satisfactory image may lead to substantial movement 
artefact when used in the investigation of patients in the hyperacute phase of 
stroke. The ability to visualise and quantify early ischaemic cerebral injury is 
essential if design of clinical trials of neuroprotective therapies is to be 
optimised. Looking further into the future, early and accurate diagnosis of 
cerebral ischaemia will permit rational and judicious use of neuroprotective 
and thrombolytic treatment.
tissue. It is postulated that although this area is at risk of imminent infarction,
i
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One of the theories underlying the development of neuroprotective agents is
the concept of the ischaemic penumbra. This is an area of abnormally low
perfusion thought to surround a central core of acutely-infarcted cerebral
' v:
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restoration of blood flow could result in reversal of the ischaemic change and
restoration of normal function. The ability to visualise this penumbra would 
permit accurate, early diagnosis, provide prognostic information early in the
-El
course of the illness and facilitate a rational decision regarding treatment in 
the hyperacute phase. As mentioned above, acutely-ischaemic brain cells 
swell and accumulate water due to membrane dysfunction. Regions affected 
by this process are not seen using conventional MR sequences or CT.
Diffusion weighted magnetic resonance imaging is a relatively new technique
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that detects the altered movement of water molecules through acutely- 
ischaemic brain tissue and hence allows localisation and quantification of
hyperacute ischaemic lesions
Diffusion refers to the movement of molecules from areas of high 
concentration to areas of low concentration. This process occurs due to the 
random Brownian motion of molecules in solution. The rate of diffusion is 
dependent on the kinetic energy of the molecules and so is affected by 
temperature. The movement of water molecules through the brain is not truly 
random due to the presence of cell membranes and so the term “apparent”
.V ;diffusion is used. The apparent diffusion of water molecules through brain 
parenchyma is detected with the addition of two strong gradient pulses to an 
otherwise standard pulse sequence. The first dephases the proton spins and 
the second completely rephases those protons which have not moved in 
position. When movement of protons occurs in the time between the two 
pulses, the spins are not perfectly in phase and signal attenuation results. The 
degree of signal attenuation depends upon both the degree of proton 
displacement and the strength of the diffusion weighting.
I
Although diffusion-weighted imaging has been used in the investigation of 
many human diseases, the technique has had greatest impact in the imaging 
of stroke. Prior to the development of diffusion imaging, identification, 
localisation and quantification of ischaemic cerebral damage using non- 
contrast magnetic resonance techniques was only reliable at least six hours 
after onset of symptoms. Using diffusion techniques, areas of infarction can
r,#
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be visualised within minutes of onset of experimental stroke in cats,®"^  and 
lesions as small as 4mm in diameter have been visualised within 100 minutes 
post ictus in humans On diffusion-weighted images, regions of ischaemic 
cerebral damage are visualised as areas of abnormally high signal intensity.
The increase in signal represents a region of reduced net diffusion, or low 
apparent diffusion coefficient. The abnormalities observed on diffusion- 
weighted images usually disappear over 5-14 days as the pathophysiological 
processes to which the technique is sensitive resolve. The use of this 
technique has recently been validated as a tool for the early investigation of 
acute stroke in humans. The intensity of signal (hence the size of decrease in 
apparent diffusion coefficient) would appear to correlate directly with the 
degree of cerebral ischaemia and inversely with the likelihood of reversal of 
the radiologic change if the ischaemic area is reperfused. The clinical 
significance of this observation is yet to be established.
Caution is required in the interpretation of these images as other factors may 
cause hyperintense lesions on a diffusion-weighted image. The most 
commonly encountered of these is diffusion anisotropy, which is due to 
unilateral diffusion of water molecules along the “path of least resistance” 
perpendicular to the white matter tracts. Early studies with DWI in patients 
with stroke used long image acquisition times which lead to some movement 
artefact in a substantial proportion of images. The development of faster 
diffusion weighted sequences (using, for example, echo-planar imaging 
techniques which enable very rapid image acquisitmn) has gone some way 
towards obviating this problem.
ÎiT"I
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Assessm ent o f cerebral perfusion using magnetic resonance
>n addition to the visualisation and quantification of cerebral ischaemia,
cerebral perfusion may also be assessed using recently developed
techniques. Perfusion studies may be performed by "tagging" inflowing blood .'i
using RF pulses or by injecting a bolus of contrast medium and following its
progress through the cerebral circulation. The former method has the
advantage of being non-invasive. Blood vessels leading into the slice to be
studied are subjected to alternating radiofrequency pulses which, when
summated, result in no net radiofrequency signal. Blood flowing into the
designated slice is met with a different echo-planar radiofrequency pulse
which alters the spin of the protons within it, leading to the generation of a
radiofrequency signal. The intensity of the signal is proportional to the amount
of blood flow and as a result a map of cerebral perfusion can be constructed.
This technique is known as Echo Planar Imaging Signal Targeting with 
Alternating Radiofrequency (“EPISTAR").
Dynamic contrast-enhanced perfusion imaging involves tracking a bolus of 
intravenous contrast agent as it passes through the cerebral circulation. Rapid 
sequential imaging sequences are used to track the progress of a bolus of 
contrast agent through the cerebral circulation. The contrast material causes 
loss of signal intensity, which can be plotted over time. This data can be
;
analysed to calculate cerebral blood volume, mean transit time (MTT) of the 
contrast agent and hence relative cerebral blood flow, which is a function of 
these two parameters. True quantitative analysis of blood flow is possible, as
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the amount by //hich the contrast agent alters signal intensity is directly 
proportional to the blood volume of the area being studied.
The ability to quantify cerebral blood flow using magnetic resonance has 
potentially useful clinical applications in the context of acute cerebral 
ischaemia. The technique is sensitive to relatively minor degrees of 
hypoperfusion and does not rely upon the development of cellular ischaemic 
dysfunction. It ^as been postulated that the use of perfusion studies in 
conjunction with diffusion weighted and conventional MR sequences will 
permit a comprehensive assessment of the cerebrovascular status of the 
patient with acute stroke. Conventional T2-weighted images will exclude 
haemorrhage and may reveal an ischaemic lesion between 6 and 8 hours old. 
Hyperacute diffusion weighted and perfusion sequences may confirm clinical 
diagnosis of ischaemic stroke in patients with clinical signs but normal T2 
scans. These novel techniques may also provide some prognostic information 
and consequently permit rational decisions to be made concerning 
neuroprotective and thrombolytic treatment at the earliest possible stage of 
the event. The ability to exclude haemorrhage, confirm ischaemia and 
possibly predict potential infarct progression using only one imaging modality 
represents a significant advance in the investigation of acute stroke. This 
should be of great benefit in the development and eventual clinical 
implementation of neuroprotective treatment.
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1.10 Throm bolytic therapy for acute ischaemic stroke
In the United States thrombolysis is now established management for
selected patients with acute ischae--'" c stroke presenting within 3 hou's of 
onset of symptoms. As yet thrombolysis is unlicensed in Europe but is 
undergoing further clinical evaluation and assessment.
Thrombolysis has been used for a number of years in the management for 
patients with myocardial infarction and its efficacy has been demonstrated by 
a number of large randomised, placebo controlled trials. Thrombolysis leads 
to reperfusion of vessels occluded by coronary atherothrombosis which in turn 
reduces mortality and preserves left ventricular function.
Most strokes are atherothrombotic or embolic (85%) while the remainder are 
haemorrhagic. It was hoped that the same 'open artery hypothesis’ would
hold true for patients with ischaemic or non-haemorrhagic stroke i.e. that early 
reperfusion would improve both mortality and functional outcome. In patients 
with stroke it appears that a central core of densely ischaemic tissue is 
surrounded by a ‘penumbra!’ zone of potentially salvageable tissue which is 
amenable to either neuroprotective or reperfusion therapy. The potential risks 
of thrombolysis are predictable from what we already know of the 
pathophysiology of stroke. Reperfusion injury may occur when toxic free 
radicals and inflammatory cells enter an ischaemic area following 
spontaneous reperfusion and haemorrhagic transformation is commonly seen 
in patients with large infarcts. Certain groups of patients could be thought of 
as at higher risk of secondary intracerebral haemorrhage as a result of
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thrombolysis. Elderly patients already have a higher risk of spontaneous 
intracerebral haemorrhage, as have hypertensives and patients with embolic 
rather than simple occlusive atherothrombotic strokes Delayed thrombolysis 
may simply lead to reperfusion of already irreversibly infarcted tissue and 
increase the risk of haemorrhage. When trials of thrombolytics were devised 
these issues were considered and are reflected in the design, entry and 
exclusion criteria of the studies. All studies incorporated a variable ‘time 
window' outwith which patients were ineligible, all patients underwent CT 
scanning to exclude intrace re bra I haemorrhage as the primary pathology and 
some studies excluded large infarcts and hypertensive patients. The analysis 
of treatment efficacy is crucial in the design and interpretation of any trial of 
stroke therapy. Most studies incorporated a validated functional outcome 
score, for example the Barthel score.®® These scores describe the patients’ 
ability to perform activities of daily living. More detailed assessments of 
neurological function were also made using, for example, the Scandinavian 
Stroke Sea le.
Streptokinase studies
The MAST-E (Multicentre Acute Stroke Study- Europe)®® and ASK (Australian 
Stroke Study)®® treated patients with streptokinase (1.5 M units over 1 hour) or 
placebo within 6 and 4 hours respectively. In both studies there was an 
increase in early mortality sufficient to result In the safety committees 
abandoning both studies prior to completion. This correlated with a high 
incidence of complicating intracerebral haemorrhage, l.n the MAST-E study
i
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36% {n=156) patients treated with streptokinase Vs 3% {n~ 154) placebo 
patients suffered a fatal haemorrhagic transformation of infarct.
The MAST-1 (MAST-ltaly) study evaluated treatment with SK and aspirin 
compared with SK or aspirin alone or p l a c e b o . A g a i n  the results suggested 
an increase in early mortality which was more marked in patients receiving 
both SK and aspirin, while aspirin alone appeared to be safe but of no clear
benefit.’'®^
Meta-analysis of all streptokinase results failed to reveal factors which 
predisposed to early mortality. Streptokinase significantly increased early 
mortality while there may have been a trend towards improved outcome in 
survivors. To date, no randomised controlled trial has supported the use of 
intravenous streptokinase as therapy for acute ischaemic stroke. Further 
studies of streptokinase using different patient selection criteria, lower doses 
of thrombolytic and prohibition of antiplatelet or anticoagulant co­
administration have been proposed however at present no such trial is 
underway. Although there remains some debate, it is unlikely that 
streptokinase will have any role in the management of acute ischaemic stroke.
Recombinant tissue plasminogen activator studies
Four major trials have evaluated the role of recombinant tissue plasminogen 
activator frt-PA) in patients with acute stroke. There are theoretical reasons 
why rt-PA may be more effective: first rt-PA Is known to be more 'clot specific’
I
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that is it causes less generalised activation of plasminogen, instead having a 
more selective action at the site of the clot itself: this may make haemorrhagic 
complications less likely. Second rt-PA is less antigenic than streptokinase 
and is not associated with a fall in blood pressure during the infusion. This 
may be of significance as reducing blood pressure immediately after 
ischaemic stroke has been associated with worse outcom e/^ Finally, 
angiographic studies in patients with acute myocardial infarction suggest rt-PA 
is more effective than streptokinase in reperfusing occluded coronary vessels. 
The ECASS 1 (European Co-operative Acute Stroke Study)'®' the NINDS 
(National Institute of Neurological Diseases and Stroke rt-PA Stroke Study)^®^ 
and ECASS 2^ ®® studies evaluated rt-PA at doses of 1.1 mg/kg. 0.9 mg/kg 
and 0.9 mg/kg respectively. Patients were treated within 6 hours in the 
ECASS studies and 3 hours in the NINDS study. The Alteplase Thrombolysis 
for Acute Non interventional Therapy in Ischaemic Stroke (ATLANTIS) study 
used a dose of 0.9 mg/kg administered within an initial time window of 6 
hours. The time window was altered twice during the study. Although the 
results of the ATLANTIS study are not yet published, the trial methodology 
and preliminary data are briefly presented below.
ECASS1
The higher dose of rt-PA used in the ECASS 1 study is equivalent to that used 
in the treatment of patients with myocardial infarction. Dose ranging studies 
have shown an increasing incidence of complicating haematoma formation in 
patients receiving doses greater than 0.85 mg/kg, and this could have 
contributed to the increased incidence of haemorrhages seen in the ECASS 1
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study. The results of ECASS 1 are also notable for the large proportion of 
patients excluded from the target population analysis (109 out of 620 
randomised). The protocol intended to e/ciude patients with greater than one 
third MCA territory stroke on CT, i.e. those with large infarcts. Sixty-six such 
patients were randomised, constituting the largest group of protocol violators. 
Survival in protocol violators was significantly worse than for those meeting 
the entry criteria. While analysis of the target population results suggested an 
improvement in functional outcome at 3 months (p=0.03) the more rigorous 
intention to treat analysis was negative. Mortality was non-significantly higher 
in the rt-PA group in both ITT and TP analysis. In summary the ECASS study 
did not show enough benefit to justify thrombolysis with rt-PA up to 6 hours 
after stroke onset although an improvement in functional outcome (Barthel 
and Rankin score) was seen in the target population analysis of the rt-PA 
receiving patients.
NINDS
The National Institute of Neurological Disorders and Stroke rt-PA Stroke 
Study assessed a lower dose of rt-PA (0.9mg/kg) given within three hours of 
onset of CT confirmed ischaemic stroke. The results suggest an improvement 
in functional outcome at 3 months, with those in the treated group 30% more 
likely to have negligible disability at this timepoint. There was no difference in 
mortality in the actively treated patients although there was an increase in 
symptomatic intracerebral haemorrhage 7% Vs 1% (rt-PA Vs plac). Mortality 
ascribed to intracerebral haemorrhage was 3^': Vs 0.3%.
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ECASS 2
The aim of the ECASS 2 study was to investigate the safety and efficacy of rt- 
PA given in a dose of 0 9 mg-kg within 6 hours of onset of ischaemic stroke. 
Strenuous efforts to improve the quality of CT interpretation were made, and 
significantly fewer intracranial haemorrhages were seen in comparison with 
the original ECASS study. The primary outcome measure was the proportion 
of patients reaching modified Rankin^®'^ Scores of 0 or 1 (i.e. little or no 
disability) at three months. The study failed to demonstrate a statistically 
significant difference between treated and placebo groups; however when the 
outcome measure was re-dichotomised to define good outcome as mRS of 0- 
2, a beneficial effect of rt-PA was seen. The authors concluded that rt-PA 
treatment leads to a clinically relevant improvement in outcome without 
increased morbidity and mortality despite increased symptomatic 
haemorrhage, however the failure of the trial to demonstrate efficacy using 
pre-determined endpoints has led to the widespread interpretation of the trial 
as neutral. Incorporation of the ECASS 2 data into a meta-analysis o f trials of 
rt-PA in acute stroke reveals a favourable odds ratio of 0.67 (95% Cl 0.56 - 
0,80) with respect to death and disability.
ATLANTIS
The ATLANTIS study was designed to assess the safety and efficacy of 
intravenous rt-PA 0.9 mg/kg within 6 hours of ischaemic stroke. Two years 
after recruitment commenced the time window was changed to 0-5 hours due 
to adverse interim safety analysis in the 5-6 hour group. After a further three 
years the time window was further modified (3-5 hours) due to the results of
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I
■ ÿî:.a
the NINDS study. W ith the exception of the time window, entry criteria were 
very similar to those employed by the NINDS investigators. The ATLANTIS 
study was terminated prematurely in July 1998 following further interim safety 
analysis which concluded that “treatment was unlikely to prove beneficial”. 
Although full data have not yet been published, it is understood that the use of 
intravenous rt-PA beyond three hours after stroke onset is not supported by 
the ATLANTIS study.
Conclusions
The NINDS study was the first to demonstrate that early intervention can 
improve the outcome for patients with acute ischaemic stroke. The ECASS 2 
study failed to reproduce the convincingly positive results of the NINDS trial; 
however meta-analysis suggests a beneficial effect of intervention with rt-PA. 
Thrombolysis with intravenous rt-PA in patients with acute ischaemic stroke 
can be justified when used judiciously within an experienced centre. Although 
it has been argued that the potential benefit of streptokinase has yet to be 
fully investigated/®® on the basis of current evidence its use cannot be 
justified in the context of acute ischaemic stroke.
1.11 Rationale for the studies performed
The theme of the studies presented in the following chapters is that outcome 
following stroke may be influenced or predicted. The work presented 
addresses several different of facets of stroke management including acute 
therapy (chapters 3 and 7), brain imaging (chapters 5 and 6) and secondary 
preventative strategies (chapters 2 and 4). The broad range of factors which
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may influence prognosis after stroke has necessitated a variety of 
investigative approaches both prospective and retrospective.
Chapter two reports a study designed to investigate the effect of intervention 
with the angiotensin converting enzyme inhibitor perindopril upon blood 
pressure, cerebral perfusion and renal perfusion in hypertensive stroke 
patients with carotid artery disease. There is little published evidence to guide 
clinicians treating such patients: failure to control blood pressure ,s associated 
with the risk of recurrent stroke and other morbidity however intervention to 
lower blood pressure carries the theoretical risk of cerebral hypoperfusion 
within the territory of a stenosed carotid artery. The angiotensin converting 
enzyme inhibitor perindopril is known to reduce blood pressure without 
adversely affecting cerebral perfusion in the context of acute ischaemic 
stroke: I hypothesised that a similar relationship would be observed following 
treatm ent of non acute stroke patients with carotid artery disease. This study 
is intended to provide a little evidence for clinicians dealing with secondary 
prevention of stroke in a difficult patient population; further research into the 
mechanistic basis of the observations described is required.
In chapter three a pilot study of rigorous giycaemic control following Ischaemic 
stroke is examined. Recent evidence has suggested that hyperglycaemia 
(blood glucose > 8 mmol/L) at the time of ischaemic stroke is associated with 
poor outcome. A large definitive study to investigate the potential benefit of 
intervention with insulin in hyperglycaemic acute stroke patients ‘s required; 
the study presented sought to investigate the safety and feasibility of one
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method of giycaemic control in this population. This “proof of concept" study is 
necessary before a larger trial, powered to provide evidence of treatment
efficacy, can be performed.
I
Chapter four reports a retrospective study designed to further investigate the
r
relationship between lipid profile and outcome after stroke. There has been 
much debate over recent data which suggested that low serum cholesterol 
concentration at the time of stroke is associated with poor prognosis. Although 
triglyceride concentration is an established risk factor for the development of 
vascular disease, the prognostic significance of triglyceride concentration 
following stroke has been largely unexplored. The findings of the study 
reported in chapter four extend our knowledge of the prognostic significance 
of lipid parameters following stroke however the mechanistic basis for the 
observations remains elusive and further study will be required before any 
therapeutic implications can be derived.
The study reported in chapter five addresses the prognostic implications of 
visible infarction on CT scan following lacunar stroke. Prognosis following
'■si
lacunar stroke is variable and few reliable indicators o f eventual outcome
have been identified in this group of patients. Previous studies have examined 
the effect of infarct size on outcome and the prognostic significance of early 
changes on CT scan following ischaemic stroke; no published study to date 
has examined a large cohort of patients with small subcortical cerebral 
lesions, correcting for other factors known to influence outcome. Early 
acquisition of prognostic information may facilitate provision of appropriate
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rehabilitation and enable more efficient use of scarce resources. The aim of 
the work presented is to investigate the potential prognostic significance of an
investigation that is routinely accuired and easily assessed
With the advent of acute therapies for acute ischaemic stroke, a greater need 
for reliable early brain imaging has evolved. As discussed above, 
interpretation of current conventional brain imaging modalities early after 
ischaemic stroke is unreliable. The ability of diffusion-weighted magnetic 
resonance imaging to detect acute ischaemic stroke has been established 
and the technique is being increasingly applied in clinical practice, however 
the implementation of diffusion-weighted magnetic resonance imaging has 
been limited by the relatively high technical specifications required. Chapter 
six describes the development and implementation of a new diffusion- 
weighted magnetic resonance sequence which requires significantly lower 
technical capabilities and can hence be employed by centres hitherto unable 
to use the technique. The feasibility and clinical utility of the new sequence in 
the investigation of patients with acute ischaemic stroke are critically 
assessed, and areas of further potential for development are identified. 
Although the work presented does not represent an entirely new development 
in magnetic resonance imaging, it is hoped that the sequence described will 
extend the range of imaging modalities available to centres with less powerful 
magnetic resonance imaging machines.
Chapter seven reports the preliminary experience of thrombolytic therapy in a 
British stroke centre. As intravenous thrombolytic therapy for ischaemic stroke
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is not widely used in the UK, little evidence of the safety of the treatment 
within UK stroke units exists. Significant differences in the provision of acute 
stroke care between the United States of America and the United Kingdom 
make interpretation of sim ilar American studies difficult. Despite the relatively 
small numbers of patients treated it is hoped that this report will contribute to 
the ongoing debate over the implementation of thrombolytic therapy in British 
clinical practice.
67
Chapter Two
The effect of perindopril on cerebral and renal perfusion in stroke patients
w ith carotid disease
68
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2.01 In troduction
Control of high blood pressure is the cornerstone of primary stroke prevention. 
A reduction in mean arterial blood pressure of 5 mmHg reduces population risk 
of stroke by approximately 30%.®® The effect of blood pressure control on 
secondary prevention of stroke is less well defined, however the benefit is likely 
to be greatest in stroke patients with underlying carotid or intracranial arterial 
disease. Although little prospective evidence on the effect of blood pressure 
control on secondary stroke prevention is available at present, a large multi­
centre randomised placebo-controlled study (PROGRESS) designed to clarify 
the relationship is underway and is due to report in 2001. The PROGRESS 
study has enrolled 6038 patients with cerebrovascular disease and 
normotension or mild to moderate hypertension, and is examining the effect of 
the angiotensin converting enzyme inhibitor perindopril alone or in combination 
with a thiazide diuretic on secondary incidence of stroke. Perindopril is an ACE 
inhibitor with a gradual onset of action and a relatively long half-life allowing 
once daily dosing. It is less likely to cause first-dose hypotension than captopril 
or enalapril.^®®
Little evidence exists to guide the choice of antihypertensive agent, or the 
timing of its introduction following the cerebrovascular event. In the first few 
days after stroke, cerebral autoregulatory mechanisms are deranged, hence 
blood pressure fluctuations may lead to significant changes in cerebral
69
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,perfusion. Some conventional antihypertensive medications may lower cerebral
administration o f angiotensin converting enzyme (ACE) inhibitors to patients 
early after ischaemic s t r o k e . T h i s  is thought to be due to increased vessel
severe carotid stenosis or carotid occlusion.
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blood flow and worsen outcome after acute ischaemic stroke probably as a 
result of reduced cerebral perfusion within and adjacent to the affected area.^®^ 
In acute ischaemic stroke patients, clinical trials involving early administration 
of agents which may lower blood pressure such as nimodipine and lifarizine 
have shown a correlation between blood pressure reduction and poor clinical 
o u t c o m e C o n v e r s e l y ,  more recent studies have suggested that no 
clinically-significant change in cerebral perfusion occurs following
#
1
■f
wall compliance and dilatation of the extracranial vessels.
r?
8
IPoor cerebral perfusion is associated with a greater risk of stroke in patientswith carotid disease.^®® Since patients with recent stroke who may have 
unrecognised carotid disease are already treated with antihypertensive drugs 
and as they will form an unidentified sub-group of the PROGRESS trial, it is 
desirable to discover the effects of such treatment on cerebral perfusion. As 
ACE inhibitors are also known to impair renal function in patients with critical 
renal artery stenosis and the prevalence of clinically-significant renal artery 
disease in patients with cerebrovascular disease is unknown, we sought to 
investigate effect of ACE inhibitors on cerebral perfusion and glomerular 
filtration in the sub-group of hypertensive stroke patients with moderate to
1"
2.02 M ethods
We performed a randomised, double-blind, placebo controlled study of oral 
perindopril (4 mg daily for 14 days) in patients with a CT or MRI confirmed 
diagnosis of ischaemic stroke, mild to moderate hypertension (mean arterial 
blood pressure greater than 100 mmHg) and carotid disease ranging from 
moderate stenosis to occlusion as assessed by Doppler ultrasonography. 
Patients whose index stroke had occurred between two weeks and six months 
prior to randomisation were considered eligible. Three consecutive blood 
pressure readings were required to fall within the inclusion range over a period of 
not less than 24 hours prior to randomisation. Patients with potentially operable 
carotid disease were excluded from the study in order not to delay surgery, as 
were patients with pre-existing moderate to severe renal impairment (serum 
creatinine > 200 pmol/lit). Any pre-existing antihypertensive therapy was 
continued for the duration o f the study, as shown in table 2.1.
Ethical approval was obtained from the West Ethical Committee, and patients 
gave written informed consent to participate. Clinical and neurological 
assessment using the NIH stroke scale^^® was made prior to study entry and 
repeated on day 14. Blood pressure was measured semi-automatically using 
Marquette oscitlometric equipment (Marquette Electronics, Wisconsin) pre 
treatment in triplicate and then hourly in triplicate for the first 8 hours after 
dosing. Blood pressure was repeated in triplicate at 24 hou's and at two weeks.
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Total carotid blood flow was calculated from bilateral internal carotid artery
insonat’on (Acuson 128. 5 MHz probe, Acuson. California) Arterial flow v-as 
calculated as:
camera. On each occasion 500 MBq ®®^ T^c HMPAQ dissolved in 5 millilitres of
I
I
[tc X (diameter)^ x mean ve locity] / 4
Details of Doppler methods employed have been published p re v io u s ly .M id d le  
cerebral artery velocity and resistance index were measured by transcranial 
Doppler (Nicolet EME TC2000, 2 MHz probe, Nicotet, Warwick, UK). Doppler 
recordings were taken pre-treatment, at 2.5. 5.5, 7.5 and 24 hours post dose and 
at 2 weeks. Routine safety biochemistry and haematology were collected at entry 
and at the conclusion of the study. Glomerular filtration rate was measured using 
chromium (®^Cr) radiolabelled ethylene diamine tetraacetic acid (EDTA) prior to 
dosing and at two weeks. Regional cerebral perfusion was measured using ®®^c 
hexamethyl propylene amine oxide single photon emission computed 
tomography (HMPAO SPECT) pre-dose and at the estimated time of peak drug
effect (approximately 6 hours) following first dose of perindopril or placebo. 
Quantification of cerebral blood flow was obtained using a technique described
by Matsuda^^^’^^ ® which involves dynamically imaging the bolus injection of ®®^Tc 
HMPAO, and using this as a reference level.
SPECT was undertaken in the department of nuclear medicine of the Western 
Infirmary using a Picker Prism 2000XP large field of view double-headed gamma
Î
0.9% saline was injected as a bolus over one second through an 18-gauge |
IL
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intravenous catheter, followed by a further flush bolus of 10 millilitres of 0.9% 
saline. An anterior image 200x1 s frames was then acquires The patient’s 
head and as much as possible of their heart were included in the field of view. 
SPECT imaging was undertaken 15 minutes later using a c 'cu la r orbit and 
acquiring 60 angles around 360° with 20s per angle. Analysis of the SPECT data 
was undertaken using a combination of Picker supplied software and some 
specialised software written in house. The data were reconstructed using a back 
projection algorithm with a Butterworth filter of order 3.14. Attenuation correction 
was undertaken using the Chang algorithm. A brain perfusion index (BPI) was 
calculated from the first pass data as described by Matsuda.^^^'^^® The 
unaffected hemisphere was used as the reference region. The reconstructed 
data were reorientated to transaxial oblique slices (8mm thick) parallel to the 
orbito-meatal line. Image registration was undertaken, registering the two sets of 
SPECT data for each of the patients.
An elliptical region of interest was manually fitted to the outer edge of each 
transaxial oblique slice for each of the sets of data and a set of templates 
constructed as previously d e s c r i b e d . R e g i o n a l  cerebral blood flow in 
ml/100g/min was then calculated in each of the segments of the template using 
the previously obtained BPI. The difference in regional cerebral blood flow can 
then be calculated for each of the segments.
73
Measurement of glomerular filtration rate was achieved using the standard single
■ |
■U;;|
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injection method A solution of ®^Cr-EDTA with a total activity of 1 G MBq was 
administered as a bolus injection. Blood samples were drawn at baseline 
(immediately prior to the injection) and at 2, 3 and 4 hours following the injection.
The plasma activity of each of these samples was measured and the rate of 
decline of plasma activity was used to estimate the glomerular filtration rate.
Results were analysed by repeated measures ANOVA and ANCOVA with the 
use of Statistica for Windows version 5.1 (StatSoft inc. OK) and Arcus Quickstat
74
Biomedical version 1.2 (Research Solutions. UK). W ith a sample size of 24 
patients we expected to detect a difference in cerebral perfusion (as assessed 
by carotid Doppler) of 16% with 80% power.
2.03 Results 
Tolerance and Safety
A total of 24 patients were recruited into the study. Patients were well matched 
with regard to age, sex, baseline blood pressure and stroke severity as assessed
by NIH score. The clinical details, brain imaging and carotid Doppler findings of 
patients at entry into the study are shown in Table 2.1.
'.I'Patient one in the treated group was withdrawn on day 3 of the study following
an episode of acute renal failure which necessitated temporary haemodialysis.
Serum creatinine at baseline had been 170 umol/L, serum potassium 4.9 
m m c"L  Rout'^e safety bloods pe^om ied on day 3 revealed rises in both of 
these parameters to 240 pmol/L and 9.0 mmol/L respectively. Temporary 
haemodialysis was required to reverse the hyperkalaemia, and biochemical 
parameters returned to pre-morbid levels within two days. The patient was well at 
the conclusion of the study; he was normokaiaemic with serum creatinine levels 
consistently between 160 and 175 pmol/L without renal replacement therapy. No 
other adverse events were encountered. With the exception of the subject 
mentioned, no significant change in safety bloods was seen. Mean NIH scores 
improved in both groups over the duration of the study. No difference in 
improvement between the groups was observed.
Blood Pressure
A significant fall in systolic (p=0.028), mean arterial (p=0.017) and diastolic 
(p=0.04) blood pressure was observed in perindopril-treated patients compared 
with the placebo group. Figures 2.1, 2.2 and 2.3 show change in blood pressure 
expressed as percentage change from baseline for each group. Figure 2.4 
shows the absolute values of mean arterial blood pressure at each timepoint. At 
baseline, blood pressure was 161 ±17.6 / 86r7  in the perindopril group and 
164=17.5 / 85=8.6 in the placebo group After two weeks' treatment blood 
pressure was 143+22.6 / 77±13.4 in the perindopril group and 163±16.1 / 86+8 in 
the placebo group, i.e. a placebo-corrected fall of 17 / 10 mmHg, No associated 
change in heart rate was seen in either group (figure 2.5).
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Middle Cerebral Artery Velocity and Resistance Index
Successful insonation of both middle cerebral arteries was achieved in seven of 
the treated patients and eight of the placebo patients. No significant difference in
ui
Internal Carotid A rtery Flow
No significant difference in total internal carotid artery flow was seen in the 
treated group compared to the placebo group (p=0.37). Figure 2.6 shows the
if. 
.1
percentage change in total internal carotid artery flow at each timepoint for 
treated and placebo groups. A non-significant trend towards an increase in total
internal carotid artery flow was observed on the first dosing day. In the treated 
group, the 95% confidence interval for percentage change in ICA flow from 
baseline at 5.5 hours post dose ranged from -3.8%  to +41.4%. The equivalent 
confidence interval in the placebo group ranged from -14.6%  to +21%. In treated 
patients with asymmetrical haemodynamically-significant carotid artery lesions, 
no significant difference in relative flow through each artery was observed. 
Absolute values for blood flow through affected and unaffected arteries from 
such patients in the treated group are given in figures 2.7, 2.8 and 2.9.
change in middle cerebral artery velocity over time was seen in the treated group
-compared to the placebo group (p=0.46). These data are shown graphically in
'
figure 2.10. The middle cerebral artery resistance index is a measure of arterial 
tone and distensibility. No significant difference (p=0.07) in the change of this 
parameter was observed between the two groups (figure 2 11),
8
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G lom eru la r F iltra tion Rate
Figure 2.12 shows the mean glomerular filtration rate (± 2SE) for each group at 
caseline and at two weeks. No significant change was seen within or between 
groups (p=0.6). Repeat GFR estimation was not performed on the patient who 
aeveloped acute renal failure.
SPECT M easurem ents
22 of 24 patients completed the SPECT protocol. One patient in the treated 
group (patient 11) failed to complete the SPECT protocol due to claustrophobia; 
in one placebo recipient (patient 12) the SPECT data images were unsuitable for 
analysis. An example of one of the SPECT studies obtained, including the 
template used for analysis, is given in figure 2.13. Analysis of both whole 
hemisphere and focal brain perfusion indices was undertaken. Figure 2.14 
shows the percentage change in whole hemisphere brain perfusion index (BPI) 
from baseline for both the affected and unaffected hemispheres in both treated 
and untreated groups. No significant deviation from baseline was observed in 
either treated or untreated groups (p=0.43). No significant difference between 
placebo and active groups was observed. Figure 2.15 shows the percentage 
change in BPI within the template zones which contained or were immediately 
adjacent to the ischaemic lesion. No significant difference in percentage change 
m peri-infarct perfusion was seen either between or within groups following 
cerindopril administration (p=0.27).
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12.04 D iscussion
Perindopril lowered blood pressure without adversely affecting global or regional icerebral perfusion in hypertensive stroke patients with moderately stenosed to i
occluded carotid arteries. O f twelve patients treated with perindopril, one patient
developed acute renal failure with required temporary haemodialysis. The study
was not designed to demonstrate any long-term effect on neurological outcome, hi?
however no drug-associated neurological deterioration was seen.
I 
iIn the execution of this study I have adopted some of the methodology of an 
earlier study^®® designed to investigate the effect of perindopril upon cerebral 
perfusion early after stroke. The technique used by both studies to assess 
internal carotid artery blood flow assumes that the lumen of the vessel being 
studied is cylindrical, i.e. that the cross-sectional area of the vessel can be
. Ïcalculated using its diameter. If the atheromatous lesions in the arteries of the 
patients studied cause a non-concentric reduction in cross-sectional area of the 
vessel, errors may be introduced in the calculation of internal carotid artery flow.
Although this may lead to inaccuracies of quantitative ICA blood flow 
measurement, no significant change over time in arterial diameter was seen 
within (p=0.7) or between (p=0.31) groups; hence the comparison of the 
magnitude of change in flow between groups remains valid.
The potential source of inaccuracy may influence the power calculation of the 
study The calculation was based upon variability data acquired during earlier 
studies of patients with normal carotid arteries, and suggested that with a sample 
size of 24 patients, a 16% difference in internal carotid artery flow could be 
detected with 80% power, Examination of the variability of the SPECT data 
acquired during this study allows a further power calculation for future studies. 
Using variability data from the SPECT scans performed during this study, it has 
been calculated that a sample size of 24 patients will allow detection of a 6% 
difference in hemispheric cerebral perfusion (as assessed by SPECT) with 80% 
power.
Although a previous study has examined the effect of perindopril on global 
cerebral perfusion early after ischaemic stroke in patients with normal carotid
a r t e r i e s , t h i s  study is the first to investigate the effects of perindopril in stroke :
patients with carotid arterial disease. Control of hypertension in this group of 
patients is associated with the theoretical risk of reduction in cerebral perfusion 
distal to the site of a stenotic lesion. Patients with severe carotid arterial disease 
may have an increased prevalence of atheromatous disease elsewhere. The use 
of angiotensin converting enzyme inhibitors in patients with renal artery stenosis 
may lead to adverse consequences, and renal function should be closely 
monitored following introduction of ACE inhibitor therapy. Our data suggests that 
perindopril will reduce blood pressure without reduction in global or focal cerebral
«
,;y-
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perfusion as assessed by Doppler and SPECT respectively, however the
mechanistic basis of+^is observation mmains unclear
In rats, angiotensin II receptors within large cerebral arteries are involved in 
cerebral autoregulation following a rise in blood pressure, and inhibition of ACE 
resets cerebral autoregulation at a lower l e v e l . S t u d i e s  of the effect of ACE 
inhibition in healthy volunteers have shown reduced in blood pressure with 
increased cerebral blood flow (as assessed by transcranial Doppler). The middle 
cerebral artery flow velocity in the volunteers did not change, however the 
resistance index increased, suggesting vasoconstriction in the cerebral 
a r t e r i o l e s . ^ I n  hypertensive patients without a history of stroke, the ACE 
inhibitor captopril has been shown to increase cerebral perfusion (measured with 
Xe^^^ SPECT) while lowering blood pressure. An inverse correlation between
magnitude of blood pressure fall and mean cerebral blood flow was observed. 117
The deleterious effect of ACE inhibition upon glomerular filtration rate in patients 
with renal artery stenosis is well recognised.^A therosclerosis is a generalised 
disease and the coexistence of haemodynamically-significant atheroma in the 
renal, carotid, and lower limb vessels has been documented . ^ In  a large case- 
control study of hypertensive patients, carotid artery ultrasound revealed the 
prevalence of significant atheroma in 83% of patients with known renovascular 
hypertension and in 43% of patients with essential h y p e r t e n s i o n . A n  overall 
trend for patients with increasingly severe renal artery disease to have
80
increasingly severe degrees of carotid disease has also been reported. This
correlation lead the authors to conclude that non-invas've screening of ca-ctid 
arteries should be undertaken in patients with severe renal artery stenosis. 
The cevalence of severe renal artery stenosis among stroke patients with 
carotid arterial disease is as yet undefined.
2.05 C onclusion
We conclude that in patients without clinically-significant renal artery stenosis, 
the angiotensin converting enzyme inhibitor perindopril safely reduces blood 
pressure without adversely affecting global or focal cerebral perfusion. As renal 
artery stenosis is known to be associated with haemodynamically significant 
carotid disease and may be reliably detected using non-invasive techniques, 
screening of this patient population for the presence of renal artery stenosis 
should be considered.
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F igure 2.13 Example of a SPECT scan with template used for analysis of focal
cerebral perfusion
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Chapter Three
A randomised, p ilot study to investigate the feasibility of glucose lowering 
w ith insulin in hyperglycaemic acute ischaemic stroke patients
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3.01 Introduction
Specific therapeutic intervention can improve outcome >n patients with acute 
ischaemic stroke. Early thrombolysis is associated with a reduction in mortality 
and an improved functional o u t c o m e . O t h e r  forms of treatment (for example 
neuroprotective agents) are currently undergoing therapeutic trials. Attention has 
recently been focused upon the significance of elevated levels of blood glucose 
in patients presenting with either myocardial infarction (Ml) or stroke. Tight 
glycaemic control immediately following Ml in diabetic patients improves outcome 
at one year;^^^ however similar prospective evidence to guide clinicians in their 
management of hyperglycaemic acute stroke patients does not exist.
Preclinical evidence suggests that hyperglycaemia predisposes to poor 
o u t c o m e . ^ I n  experimental models of stroke, hyperglycaemia augments
ischaemic brain injury following cerebral ischaemia, possibly as a result of lactate 
accumulation. A more detailed discussion of the preclinical work in this field can 
be found in chapter one. In humans with acute stroke, a correlation between high 
levels of blood glucose and poor outcome has been reported in several 
s e r i e s . I t  was initially suggested that the relationship was an 
epiphenomenon and that blood sugar is elevated in patients with more severe 
strokes (as part of an exaggerated stress response): however, studies of 
biochemical markers of stress failed to substantiate this.^^^’^^  ^ Two large-scale 
studies have further clarified the nature of the relationship between acute 
ischaemic stroke, hyperglycaemia and the stress r e s p o n s e . B o t h  studies
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demonstrated an adverse effect of hyperglycaemia following acute stroke, after
correcting for stroke severity and :"her factors known to predict outcome.
Evidence accrued from these studies suggests plasma glucose level greater 
than 8 mmol/L is an independent predictor of poor prognosis. The effect of 
hyperglycaemia on mortality was considerable; the estimated relative hazard of 
1.87 calculated in one study^" was greater than for haemorrhagic versus 
ischaemic stroke, and comparable to the excess risk conferred by adding twenty 
years to a patient’s age. A randomised trial is warranted to examine the potential 
benefit of intervention with insulin to lower blood glucose after stroke, and to
define more accurately the potential risks of iatrogenic hypoglycaemia and 
disturbance of fluid balance. As discussed in chapter one, insulin may exert a 
beneficial effect through a number of local and systemic mechanisms. Through 
lowering blood glucose, insulin reduces availability of substrate for anaerobic
'glycolysis and hence may reduce lactate accumulation within ischaemic human
s
brain tissue. In addition, a neuroprotective effect of insulin acting at cerebral 
insulin-like growth factor receptors and independent of its hypoglycaemic action 
has been postulated. Systemic effects of insulin, such as correction of disturbed 
lipoprotein patterns, effects on platelet function and on plasminogen activator 
inhibitor levels may also contribute to any beneficial effect. We performed a pilot 
study to examine the feasibility of a large-scale clinical trial comparing stroke 
outcomes in hyperglycaemic patients presenting within 24 hours of stroke 
randomised to either strict or routine glycaemic control.
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3.02 M ethods
The Acute Stroke Unit of the Western Infirmary in Glasgow serves a catchment 
population of 220.000. All patients who present within 72 hours of onset of acute 
neurological deficit with no known alternative to a vascular cause are admitted 
irrespective of age or severity of neurological deficit. All clinical data and results 
of investigations are gathered prospectively. The aim is to complete all 
investigations, including computed tomography or magnetic resonance imaging 
where appropriate, within 72 hours. Patients admitted to our unit within 24 hours 
of onset of CT-confirmed ischaemic stroke, with venous blood glucose greater 
than 8 mmol/L and Glasgow Coma Scale greater than 8 were considered eligible 
for the study. Patients in whom insulin administration was considered essentia! 
(known insulin-requiring diabetes mellitus or severe metabolic derangement) and 
patients with clinical evidence of infection or congestive cardiac failure were 
excluded. After informed consent (or informed assent of relatives in patients with 
language disorder) was obtained, patients were randomised to either standard 
management' or rigorous control of hyperglycaemia. The aim of the latter 
approach was to maintain blood sugar between 5 and 8 mmol/L. Those patients 
randomised to the active treatment arm received an infusion of insulin (Human 
Actrapid, Novo Nordisk) with dosage adjustment according to a sliding scale 
(Table 3.1) together with an infusion of crystalloid (either 5% dextrose or 0.9% 
saline as dictated by blood glucose concentration). Insulin was given 
continuously via an infusion pump attached to an intravenous cannula and the
89
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dose titrated according to ttie  most recent blood sugar reading. Blood sugar
.'Monitoring was carried out every 2 hours in accordance with guidelines issued by 
our local Drug and Therapeutics Committee. The rate of intravenous crystalloid 
infusion was dependent upon cardiac status and fluid balance. The infusion of 
insulin by sliding scale and appropriate crystalloid continued for 48 hours. On
I■cessation of the infusion, any pre-existing oral hypoglycaemic therapy was re-
instituted. Patients in the control group received standard management of their 
blood sugar, which comprised the continuation of any pre-existing oral
:
hypoglycaemic therapy if swallowing was satisfactory, and blood glucose 
monitoring with the same frequency as the insulin group. Patients in the control 
group received intravenous infusion of crystalloid (0.9% saline ± 5% dextrose) for 
the first 48 hours of the study. The rate of the infusion was determined by the 
fluid balance and clinical state of the patient. Standard hospital diet was provided 
to patients in both groups if swallowing ability was satisfactory. Tube feeding was 
not instituted in any patient during the infusion period. All pre-existing oral 
hypoglycaemic therapy was discontinued in the insulin recipients; the 
antihypertensive medication of every patient recruited was discontinued in 
accordance with our protocol. Ethical approval from the West ethics committee 
was obtained prior to recruitment.
The blood glucose concentrations and infusions were monitored and rates of 
insulin delivery adjusted by ward nursing staff; protocols were provided to guide 
insulin dose titration. Blood glucose was monitored at the bedside using standard
hexokinase assay (Bayer Giucometer strips; Bayer Diagnostics. Leverkusen, 
Germany) Readings were taken at two-hourly inte'.ais Gr 48 hours after 
commencement of infusion. Supine blood pressure was measured at four-hourly 
intervals during the infusion period using Marquette oscillometric equipment 
(Marquette Electronics, W isconsin). Monitoring protocols were identical for both 
the treated and control arms of the study.
As the protocol required titration of insulin dose against regular blood glucose 
measurements, it was not practicable to conduct the study double or single blind, 
and an open study design was adopted. Patients underwent laboratory, clinical 
and neurological assessments (including NIH Stroke Scale) at baseline and 
clinical assessments were repeated one month later.
This was a pilot study designed to establish the safety of insulin treatment in 
patients with moderate hyperglycaemia following acute ischaemic stroke. 
Mortality figures at one month were collected and used as the principal outcome 
measure of the study; as other clinical and radiological assessments may have 
been prone to observer bias they were used as secondary endpoints only. 
HbA1c was collected at baseline and values less than 5% were considered as 
indicative of pre-stroke normoglycaemia. The secondary endpoints were NIH 
scores at baseline and at one month, and safety laboratory measurements, 
including assessment of the frequency and severity of iatrogenic hypoglycaemia.
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3.03 R esults 
Dem ographics
25 catients were recruited, of whom 13 were treated with insulin and 12 received 
conventional treatment. The groups were well matched with regard to age, sex, 
elapsed time between ictus and commencement of infusion, initial plasma 
glucose concentration, diabetic status and initial stroke seventy (as assessed by 
NIH score). Patient demographics are shown in Table 3.2.
Blood Glucose
The capillary glucose concentration of patients within the treated group fell to 
lower values within 4 hours of commencement of infusion and a significant 
difference in capillary blood glucose between the two groups was apparent
during the early stages of the infusion of insulin (Figure 3.1). Repeated measures 
analysis of variance revealed highly significant group (p=0.001) and time 
(p=0,009) differences. No significant group / time interaction was seen. A smaller 
proportion of insulin recipients strayed outwith the desired range of capillary 
glucose concentrations (5.0-7.9 mmol/lit) during monitoring (Figures 3.2 and 3.3). 
A significant reduction in mean area under glucose / time curve was seen in the 
insulin treated group (figure 3.4).
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Insulin dose and Infusate Volum e
Mean total insu'in dose per patient was 80.8 units in ^8 hours (SD 12). A
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histogram of insulin infusion rate at each timepoint is given in figure 3.5. Patients 
in the treated arm of the study received relatively more 5 ':  dextrose and less
0.9% saline than patients in the control group, in accordance with the sliding 
scale protocol. The mean total volume of crystalloid infused in each group is 
given in figure 3.6.
NIH Score
NIH scores were measured at baseline and at one month. Mean baseline NIH
score in the treated group was 7.6 (range 2-28). The equivalent figure in the 
control group was 8.3 (range 4-17). At one month, NIH score was unchanged or 
improved in all 24 survivors. Mean NIH score in the treated group survivors at 
one month was 3.75 (range 0-17), and 6 (range 2-13) in the control group. The 
change in mean NIH scores o f the survivors is shown in figure 3.7. Due to the 
small numbers involved, further analysis of the NIH data was not undertaken.
Blood Pressure
Supine blood pressure was measured at regular intervals during the infusion 
period using Marquette oscillometric equipment. No significant differences in 
systolic or diastolic blood pressure were observed between the groups on 
admission or for the duration o f the infusion. These data are shown in figure 3.8.
:Mortality
One death occurred in the treated group. The patient succumbed to hypostatic 
bronchopneumonia three weeks after admission with extensive hemispheric
cerebral infarction. There were no deaths in the untreated group.
3.04 Discussion
We have demonstrated that attenuation of hyperglycaemia and maintenance of 
blood glucose within a pre-defined range following acute ischaemic stroke is 
safely achievable using intravenous administration of rapid-acting insulin by 
sliding scale. The study protocol excluded comatose patients and hence allowed 
assessment of the incidence of symptomatic episodes of hypoglycaemia. In 
common with other studies of insulin administration to hyperglycaemic 
patients we found these to be rare and relatively mile One patient in the
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Adverse events
No sig-^ificant adverse events were observed ir  either during the infus on
period. One symptomatic episode, possibly attributable to iatrogenic
dihypoglycaemia occurred in one of the insulin recipients. This comprised 
subjective sensations of hunger and anxiety, and was associated with a capillary 
blood glucose reading of 4.0 mmol/lit (reference range 2.8-6.0 mmol/lit). The 
symptoms resolved promptly following oral dextrose administration, and capillary 
blood glucose had risen to 5.2 mmol/lit when retested two hours later.
treated group had symptoms consistent with hypoglycaemia, however glucose 
concentration measured during the symptoms was at the lower end of the normal 
reference range. No blood glucose readings below the lower end of the 
reference range were recorded in either group during the monitoring period. As 
can be seen from the NIH data presented, recruits into the study tended to have 
mild stroke related symptoms. The mean baseline NIH scores of patients in 
treatment and control groups were 7.6 and 8.3 respectively. In an unselected 
cohort of 200 consecutive patients presenting to our unit, the equivalent figure 
was 9.7. Although retrospective evidence suggests that the detrimental effect of 
hyperglycaemia is greatest in patients with small subcortical cerebral infarction, 
the adverse prognostic effect o f hyperglycaemia was seen across a broad range 
of stroke severity.^° Our study sought to investigate the feasibility of this method 
of blood glucose control when applied to a busy clinical stroke unit. The design of 
the study was simple and pragmatic in order to minimise the burden to nursing 
staff. All patients receiving intravenous insulin are monitored with two-hourly 
fingerprick blood glucose estimation in accordance with local protocols, and no 
significant problems with data collection were encountered during this study. 
Insulin infusions were prepared daily by either nursing or medical staff; this task 
caused no significant inconvenience for either group.
A large scale prospective study to investigate the potential benefit of intervention 
with insulin in hyperglycaemic humans following acute stroke is warranted, and 
our study has demonstrated the feasibility of one approach to metabolic
94
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intervention after stroke. Relatively little published work on the effect of insulin on
human ischaemic brain tissue exists t^ere^:-e a ca g m a tc  approach must be
issues arise; these are discussed below.
i ï
taken in the design of such a trial. Due to the paucity of evidence, a number of
■ f r
1. Hyperglycaemic threshold above which randomisation should be considered.
The recent observational study discusses earlier reported a poor outcome 
in stroke patients whose level of blood glucose exceeded 8.0 mmol/lit on 
presentation. Further analysis of the data used in that study reveals a 
relationship between poor outcome and elevated blood glucose at relatively 
lower levels of glucose concentration. The relative hazard of poor outcome is
as great at a threshold of 7.5 mmol/lit (1.7964) as it is at 8.0 mmol/lit - it may
,
be that a threshold of 7.5 mmol/lit for both recruitment and upper end of 
“target” range should be considered in the light o f this information.
2. Time window within which patients can be recruited. As the potential benefit 
of insulin in hyperglycaemic patients with stroke may arise from any of a 
number of diverse effects both local and systemic, it is difficult to argue a 
cogent case for any particular time windov/ There is evidence to suggest that 
any direct neuroprotective effect of insulin mediated by central IGF-1 
receptors and independent of hypoglycaemic action may occur exclusively 
during the hyperacute phase of stroke.''" it is also unlikely that neuronal death 
associated with excess accumulation of lactate following hyperglycaemic 
ischaemic stroke will be affected by insulin-mediated euglycaemia outwith the
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hyperacute phase. Conversely, both positron emission tomography (PET) 
and magnetic resonance scectroscopy studies have suggested that cellular 
activity within the ischaemic penumbra continues in some cases for greater 
than 24 hours after ictus In addition, evidence from other studies of 
intervention with insulin following acute vascular occlusion^^^ suggests that 
subacute intervention with insulin may be beneficial, although the underlying 
mechanisms remain elusive. Analysis of data from Glasgow^° suggests that 
elevated levels of blood sugar measured at 24 hours post ictus continue to 
confer a relatively poor prognosis. The DIGAMI study of insulin infusion 
following myocardial infarction in diabetic patients used a 24 hour time 
window. The investigators reported a significant improvement in both short 
and long-term mortality within the treated group and concluded that 
intravenous insulin therapy in hyperglycaemic diabetic patients with acute 
myocardial infarction was beneficial if initiated within 24 hours of onset. In 
addition, the prevailing erroneous perception of stroke as a non-urgent 
condition frequently leads to delay in presentation to hospital In the U.K. A 
broader time window should greatly facilitate recruitment of patients.
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Subgroup analysis of those patients treated within a shorter time window may 
permit detection of any hyperacute neuroprotective effect upon the ischaemic 
penumbra.
3. The duration of insulin infusion. As a substantial proportion of the patients 
recruited into the study will not be diabetic and will have no need of
I
hypoglycaemic therapy in the longer term, the minimum duration of insulin 
therapy must be defined, A period of 48 hcm's was used for the pilot study 
and was found to be well tolerated, with no clinically significant 
hypoglycaemic episodes: however it was observed that a substantial 
proportion of those non-diabetic individuals randomised to receive insulin 
maintained euglycaemic levels with minimal supplemental insulin towards the 
end of the prescribed dosing period. It may be that cessation of the infusion 
could be considered before 48 hours have elapsed should it become 
apparent that the supplemental insulin is no longer required to maintain 
euglycaemia. A further issue is the maintenance of long term insulin therapy. 
The DIGAMI investigators observed a continuing survival advantage of long­
term subcutaneous insulin in diabetic patients following acute myocardial 
infarction. Although the observed benefit may have been attributable to 
cessation of potentially cardiotoxic sulphonylurea therapy, it has been 
postulated that the systemic effects of insulin upon platelet function and lipid 
metabolism may be protective against further vascular events. In order to 
detect any benefit provided by insulin therapy in the longer term following 
stroke, non insulin dependent diabetic individuals recruited into the study 
could be converted to subcutaneous insulin for the remainder of the trial in a
insulin for one year after the index event would enable detection of any 
sustained benefit of ongoing insulin administration however this approach 
may lead to increased withdrawals from the study.
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fashion analogous to the DIGAMI s t u d y . C o n v e r s i o n  to subcutaneous
:i
4. The primary endpoint The pilot study used mortality alone as a primary 
endpoint, with neurological deficit (NIH score) as a secondary endpoint. 
Mortality alone was used as a primary endpoint for both statistical and 
logistical reasons. In Scotland, recorddinkage of clinical information allows 
rapid and accurate collection of mortality data with a minimum of effort on the 
part of the investigators. The initial retrospective study^° suggested a 
significant and early divergence of survival curves between hyperglycaemic 
and euglycaemic stroke patients. In addition, as the trial design was 
unblinded, the use of a primary endpoint that was not open to bias 
represented a logical choice. It may be that more functional measures of 
outcome (such as Barthel or Rankin scores) should be used and combined 
with mortality to permit dichotomised primary endpoints (such as dead or 
severely disabled versus alive and at home) in a larger, definitive study. The 
use of more widely-recognised outcome measures is to be encouraged, 
however this approach may leave the study open to criticisms of bias as the 
design is currently unblinded and implementation of a blinded study of insulin 
infusion may prove difficult.
5. The duration of follow-up. As the initial retrospective study^° indicated that the 
majority of excess early mortality in hyperglycaemic stroke patients occurred 
early, the follow-up period of the pilot study was limited to one month. It is 
anticipated that the proposed multi-centre protocol would employ a longer
98
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period of follow-up as a larger, multi-centre trial may be in a position to detect 
ongoing long te rm 'b e ne fit of intervention with insulin, particularly 'f the 
duration of insulin therapy is increased as mentioned above.
■
6. The method of insulin administration. For logistical reasons a sliding scale of 
insulin infusion was used in the pilot study. Local nursing staff were 
experienced in using this method of glycaemic control and during the pilot 
study no significant difficulties with infusion preparation or administration 
arose. The sliding scale insulin regime involves regular monitoring of capillary 
blood glucose (12 times daily) with subsequent titration of "Actrapid” insulin 
dose as delivered by a syringe driver. The dose of insulin to be administered 
varies directly with the glucose measurement and is prescribed in advance by 
medical staff. A  concurrent dextrose infusion is provided at variable rate as 
dictated by the patient’s cardiac status, metabolic status and fluid balance.
An alternative regime is also commonly used in Europe and North America.
The “GKI” regime uses infusion of a solution containing glucose, potassium 
and insulin at variable rate to maintain euglycaemia. It is relatively simple to 
administer and obviates any risk of infusion pump malfunction causing
.
iatrogenic hypoglycaemia. it is somewhat less flexible than the sliding scale
-regime as glucose and insulin infusions cannot be varied independently of 
each other. As with sliding scale insulin administration, two-hourly monitoring 
of blood sugar is routinely used. A recent prospective study has recently 
reported a similar chysiologica! but attenuated glucose response to acute
99
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stroke using the GKI r e g i m e . S o m e  problems are faced when using either 
method. Both sliding scale and GKI regimes are reactive rather than 
proactive as they respond to fluctuations in blood sugar only after they have 
occurred. Maintenance of euglycaemia can prove difficult in patients who are 
eating and drinking normally, as such patients tend to develop post-prandial 
hyperglycaemia before the insulin infusion rate is increased. While both 
sliding scale and GKI regimes have attracted criticism in the literature, 
no clearly superior alternative has yet been reported.
3.05 Conclusion
The relationship between hyperglycaemia and outcome following cerebral 
ischaemia is not yet fully understood. There is reasonable evidence to suggest 
that hyperglycaemia immediately following cerebral ischaemia is not entirely
attributable to a stress response and that it predicts a relatively poor prognosis.
Although there is a paucity of prospective data at present, current evidence 
suggests that intervention to reduce excessively high levels of blood sugar white 
avoiding hypoglycaemia is warranted, and that this can safely and effectively be 
achieved using intravenous administration of insulin by sliding scale. Larger trials 
are required to clarify optimal metabolic management following ischaemic stroke.
3%
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Table 3.1 Sliding Scale
Blood Glucose 
(mmol/lit)
Infusate
0-6 5% Dextrose
6.1-8 5% Dextrose
8.1-11 5% Dextrose
11.1-15 0.9% Saline
15.1-20 0.9% Saline
>20 0.9% Saline
Dose of Intravenous Actrapid Insulin
 __________ (Units/h)____________
0
2
3
4
5
6
Table 3.2 Patient demographics
Insulin group (n=13) Control group (n=12)
Age (± 2SE) 73.3 (6.9) 76,7(5.5)
NIH (± 2SE) 7.6(4) 8.33 (2.5)
Initial blood glucose{± 2SE) 10.7 (0.9) 10.6(0.8)
Known NIDDM 7 6
Initial HbA1c 6.2 (0.94) 5.6 (1.04)
Number of males 5 5
Initial SEP (± 2SE) 159 (10) 166(12)
Initial DBP (± 2SE) 87(5) 87(8)
H b A lO  5% 8 5
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Chapter Four
Low triglyceride, not low cholesterol concentration, independently predicts 
poor outcome fo llow ing acute stroke
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4.01 Introduction
Recent data from our group has shown an unexpected and ‘counter-intuitive’ 
association between poor stroke s jtcom e and lower serum choies'.eroi.^^® This 
finding has been corroborated by o t h e r s T h e  biological plausibility for this 
relationship is uncertain, however It has been speculated that lower serum 
cholesterol in relatively elderly patients may simply reflect poor nutritional status, 
which could predispose to a poor outcome after s t r o k e . A  second possibility is that 
high cholesterol post stroke may be protective through increasing gamma-GTj^'^^ this 
enzyme has a role in amino acid uptake and transport and thereby could reduce the 
neurotoxic effects of amino acids. Alternatively, the relationship between cholesterol 
and stroke may simply rely on (or be explained by) the immediate post stroke effects 
of inflammation on cholesterol concentrations/"*^ Whatever the mechanism, it would 
seem sensible to caution on lipid lowering therapy for prevention of stroke until better 
prospective data are available.
Cholesterol, however, is not the only lipid parameter measured in relation to 
assessment of vascular risk. Triglyceride concentration has also been linked to
coronary heart disease and stroke in prospective studies, and recent observations 
have tended to support the notion that there may be a clinically relevant interaction 
between cholesterol and triglycerides in the risk of coronary heart d i s e a s e . i n
addition there exists a strong association between triglyceride and insulin resistance. 
Indeed, hypertriglyceridaemic individuals are at increased risk of Type 2 diabetes 
meltitus, consistent with the key role of insulin resistance in both conditions.^"*"*
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Despite such associations, there are currently no data on the relationship between 
triglyceride and stroke outcome. Such information may yield further mechanistic 
i'^formation on the relationship between lipids and outcc"ie  following stroke. For 
example, if poor outcome following stroke was unrelated to low triglyceride, then this 
would imply that the cholesterol link is specific, implicating an association of low LDL- 
cholestero! (± tow HDL-cholesterol) concentrations to stroke outcome. If, on the 
other hand, low triglyceride were a strong predictor of stroke, then this would point 
towards an association also of triglyceride-rich lipoproteins with stroke outcome.
Alternatively, since hyperglycaemia is common following acute stroke and predicts a 
poor o u t c o m e , t h e r e  may be an underlying susceptibility to insulin resistance in 
such individuals.*"*" In this scenario, we may anticipate an association of high 
triglyceride with poor stroke outcome, because as noted above hypertriglyceridaemia 
is a common feature of insulin resistance.
I
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The aim of this long-term follow-up study therefore, was to explore the association 
between triglyceride and outcome following stroke. If an association was present, we 
wished also to examine whether this association was stronger than that of 
cholesterol with outcome following stroke.
4.02 Sub jects and M ethods
The Acute Stroke Unit of the Western Infirmary in Glasgow serves a catchment
population of 220,000. All patients who present within 72 hours of onset of acute 
neurological deficit with no known alternative to a vascular cause are admitted 
irrespective of age or severity of the neurological deficit. Approximately 800 patients
■ : /
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are admitted each year. A ll patients have their stroke subtype categorised using the 
Oxfordshire Community Stroke Project clinical classification, and brain imaging using 
either CT or MRl is performed vvithir "^ 2 hours of admission on all patients with a 
clinical diagnosis of stroke, Clinical, radiological and biochemical data from each 
patient are reviewed and verified by a neurologist, radiologist and stroke physicians 
before being recorded prospectiveiy on a computer database.
Biochemical data (including random glucose concentration and lipid profile) are 
obtained routinely from all patients on the day of admission. Cholesterol 
concentration was measured using a standard cholesterol oxidase antipyrine 
(CHOD-PAP) assay (Beckman diagnostics, Fullerton, Ca.). Triglyceride 
concentration was measured using a glyceryl phosphate (GPO) enzymatic 
technique. Both assays were performed using a Beckman CX4 analyser (Beckman 
diagnostics, Fullerton, Ca.). Fasting samples for glucose and lipid estimation are also 
drawn early the following morning, along with a standard battery of haematological 
and biochemical tests. In this study we used the random glucose concentration if it 
was taken; otherwise we used the fasting sample. Glucose concentration was 
recorded both as a continuous variable and as a binary variable (<8mmol/l, 
normoglycaemic; >8mmol/l, hyperglycaemic). The upper limit of normal for a fasting 
plasma glucose concentration is 6.5mmol/l. As not all glucose measurements in our 
study were fasting, 8 mmol/l was take" as the cut point for hyperglycaemia. Other 
potential prognostic variables considered were age, stroke type (ischaemic or 
haemorrhagic), admission blood pressure (systolic and diastolic), smoking status, 
presence of atrial fibrillation, time to resolution of symptoms (<72 hours or >72 hours) 
and Oxford Community Stroke Project Category. W e examined the effect of known
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surrogate biochemical markers of insulin resistance (serum urate concentration, 
serum triglyceride concentration, gamma GT concentration and serum cholesterol 
level) on outcome by constructing a proportional hazards regression model and 
incorporating them in the analysis, after adjusting for known prognostic factors. 
Patients in the study presented to our acute stroke unit between June 1990 and 
September 1997. Those with previously diagnosed diabetes or a final diagnosis 
other than acute stroke were excluded from the analysis.
hospitals or to institutions outside Scotland are not detected.
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Survival and placement follow-up were by record linkage to the Scottish deaths 
register and to a national database of hospital discharge records. The method of 
record linkage was validated in an epidemiological study of hypertension, and has 
been used for monitoring end points and adverse events in a large clinical triai. '^^®’ '^^  ^
Record linkage provides reliable patient follow up; however, admissions to private
4.03 Statistical analysis
148Our main analysis used a stepwise Cox proportional hazards regression model to 
estimate the effect of markers of insulin resistance (serum urate concentration, 
serum triglyceride concentration, gamma GT concentration and serum cholesterol
■level) on survival following stroke. A separate baseline survival function was fitted for 
each of five strata of patients defined by OCSP category and stroke type (primary 
intracerebral haemorrhage, total anterior circulation infarction, partial anterior 
circulation infarction, posterior circulation infarction, and lacunar infarction). This was 
done since these variables would not satisfy the proportional hazards assumption. ii'l:.T'
The effects of serum urate, triglyceride, gamma GT and cholesterol concentrations, 
were determined after correcting for othe- significant prognostic variables (selected 
from age, time to resolution of symptoms smoking status, systolic blood pressure, 
diastolic blood pressure, mean arterial pressure, presence of atrial fibrillation and 
hyperglycaemia). The assumption of proportional hazards was checked for all 
variables included in the model. A quadratic term for the blood pressure 
measurements was permitted in the proportional hazards modelling.
4.04 Results
We studied 1312 non-diabetic patients with computed tomography confirmed acute 
stroke and biochemistry data available. The cohort used included those patients 
previously s t u d i e d . B l o o d  samples were drawn in a fasting state within 24 hours of 
admission to our unit. The mean follow up time in survivors was 1196 days (range, 
94 to 2764 days). Table 4.1 gives the distribution of the clinical and biochemical 
features studied.
With the exceptions of serum triglyceride level and the plasma glucose level 
(continuous variable), all variables satisfied the assumption of proportional hazards. 
In the case of plasma glucose level :nis was resolved by using the binary 
representation of the variable with 8 mmol/l as the cut-off point for hyperglycaemia. 
Categorisation of the triglyceride measurement into quartiles satisfied the 
proportional hazards assumption and this representation of the variable was 
therefore used. Table 4.2 gives the results of the proportional hazards modelling.
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Increased age, presence of AF, hyperglycaemia, and hwer triglyceride level 
independently predicted (all p<0.001) higher mortality, v.- e early resolution of 
symptoms unsurprisingly was an independent predictor of lower mortality (Table 4.2). 
Although serum cholesterol level predicted outcome after adjusting for other 
prognostic factors, it did not remain significant when triglyceride level entered the 
model. Urate level and current smoking status did not independently predict 
mortality. Elevated systolic blood pressure, diastolic blood pressure and mean 
arterial pressure were not significant linear or quadratic predictors of higher mortality. 
Table 4.3 shows examples of the predicted 6 month survival for patients with 
different stroke types, serum triglyceride concentrations, and age. Figure 4.1 shows 
survival curves, estimated from the proportional hazards model, for the four quartiles 
of triglyceride level in a typical patient. Even at 6 months, there was approximately a 
20% better survival in patients in the top quartile of triglyceride concentrations 
relative to those in the lowest quartile.
4.05 Discussion
Our data suggest that the concentration of triglyceride independently influences 
survival of patients with acute stroke. More importantly, triglycéride concentration 
was more strongly predictive o f outcome than cholesterol and in fact, cholesterol 
concentration was not a significant independent predictor once triglyceride was 
entered into the model. We also examined the effect of Gamma-GT on outcome, but 
this parameter had no relationship to outcome.
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W hat is the potential explanation of our results, and do they provide any further 
insights into potential biological mechanisms for these associations? First, the 
association of low triglyceride with outcome following acute stroke argues perhaps 
more strongly against an confounding effect of inflammation in this relationship. 
Butterworth et af'^^ demonstrated that triglyceride concentration does not change in 
the first week after an ischaemic stroke; in contrast, they noted that cholesterol (and 
LDL-cholesteroi) does fall following stroke and significantly so by 1 week. Second, 
since at a total fasting plasma triglyceride concentration of 1.3 mmol/L (the median 
concentration in our cohort), the majority of measured triglyceride circulates in the 
form of very low density lipoprotein particles^"^® (which also carries cholesterol), our 
results would be more suggestive of an association of low VLDL (rather than or in 
addition to LDL) concentration with poor stroke outcome. In other words, it is the 
strong association of triglyceride in the form of VLDL with stroke outcome that 
accounts fo r the previously noted relationship of low cholesterol with outcome 
following stroke. This suggestion, however, requires direct examination in future 
studies. Third, the association of low triglyceride with poor outcome post stroke is 
consistent with a nutritional deficiency element. A significant fall in triglyceride can 
be effected with energy restriction, and independently of changes in w e i g h t . I n  
addition, there are abundant data to show that energy restriction reduces triglyceride 
much more than c h o l e s t e r o l / i n d i c a t i n g  that triglyceride is a better indicator of 
poor nutritional status.
With respect to this nutritional argument, it is of interest to note the recent
observation by Gillman et of an inverse association of dietary fat with
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development of ischaemic stroke in men. Could low dietary fat intake (or status) 
also influence long term outcome following acute stroke?
, :s
Triglyceride also correlates strongly to body mass index and waist circumference, 
and again in both sexes does so better than cholesterol.'^'^ Unfortunately information 
on weight and waist circumferences was not collected in this study but clearly such 
parameters require investigation as predictors of outcome following stroke in future 
studies.
4.06 C onclus ion
In conclusion, low fasting plasma triglyceride is a strong and independent predictor of 
poor outcome following stroke, whereas cholesterol is not. Clearly, future studies are 
needed to examine in greater detail the mechanisms explaining the association of 
lipids (and lipoproteins) with outcome following stroke.
%
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Table 4.1 Clinical and b iochem ical factors on presentation  (n=1312)
Median age 70
Male sex 646 (49)
Smoker 626 (48)
Mec an systolic blood pressure (mm Hg) 159
Me: an diastolic blood pressure (mm Hgj 90
Mec an mean arterial pressure (mm Hg) 113
Atrial fibrillation 114(9)
Ischaer c stroke 1199 (91)
Oxford classification
Total anterior circulation infarct 224(17)
Partial anterior circulation infarct 441 (34)
Posterior circulation infarct 133(10)
Lacunar infarct 386 (29)
Other 15(1)
Hemorrhagic stroke 113(9)
Symptoms resolved within 72 hours 170 (13)
Median plasma glucose (mmol / L) 6.1
Hyperglycemia 216(16)
Meaian serum cholesterol (mmol / L) 5.8
Me: an serum triglyceride (mmol / L) 1.3
Median serum urate (mmol / L) 0.32
Median serum y-GT (U / L) 29
Figures shown a^e number (percentage) of patients unless otherwise stated.
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Table 4.2 Proportional hazards modeling of mortality
Relative hazard 95% confidence interval p-value
Increasing age 
(per decade)
1 56 (1.45, 1.72) < 0.0001
increasing triglyceride level 
(per quartile)
0 84 '0 77 . 0.92) < 0,0001
Hyperglycemia 1.47 (1.18, 1.83) 0.001
Symptoms resolved 
w ithin 72hrs
0.59 (0,41 , 0.85) 0,004
Atrial fibrillation 1.37 (1,08 , 1.75) 0.009
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Table 4.3 Survival rates estimated from proportional hazards model
Oxford classification Age Triglyceride level 6-month survival rate (%)
Total anterior circulation infarct 50 years C 8 mmol / L 80.7
Total anterior circulation infarct 50 years 2 5 mmol / L 88.1
Total anterior circulation infarct 75 years C 8 mmol / L 51.1
Total anterior circulation infarct 75 years 2.5 mmol / L 67.1
Lacunar infarct 50 years C 8 mmol / L 95.4
Lacunar infarct 50 years 2.5 mmol / L 97,2
Lacunar Infarct 75 years 0.8 mmol / L 86.3
Lacunar infarct 75 years 2.5 mmol / L 91.6
"'i
I1: '
Survival rates are calculated for patients with the above characteristics and without AF, early resolution 
of symptoms or elevated plasma glucose level. 0.8 mmol / L and 2.5 mmol / L are the median serum 
triglyceride concentrations within the lower and upper triglyceride quartiles respectively.
$
I
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Figure 4.1 Triglyceride level and survival after stroke
Kapian-Meier survival curves for the four quartiles of serum triglyceride level.
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Chapter Five
The prognostic significance of visible infarction on computed tomography 
following lacunar stroke: Results of a long-term follow-up study
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5.01 Introduction
Lacunar strokes are characterised by a number of well-recognised clinical
features,^®® explained pathologically by small (0.2-15mm^), deep Infarcts caused
,by hypertension-induced changes in small perforating arteries. Lacunar 
syndromes are characterised by lack of impairment of higher cerebral functions 
such as praxis, language and gnosis. Symptoms are usually well-localised, the 
most common clinical manifestation being pure motor stroke. Other recognised 
lacunar syndromes comprise pure sensory stroke, sensorimotor stroke, 
dysarthria-clumsy hand syndrome and ataxic hemiparesis. As defined by the 
Oxford Community Stroke P r o j e c t , l a c u n a r  symptoms account for ■
approximately 25% of all presentations with ischaemic stroke. Substantial 
variability in functional outcome, and relatively few factors predictive of death or 
degree of recovery have been observed in this g r o u p . T h e  recognised 
prognostic indicators following lacunar stroke are age, degree o f neurological 
dysfunction, blood glucose concentration at presentation and functional disability 
one week after the index s t r o k e . A l t h o u g h  computed tomography (GT) of 
patients with a clinical diagnosis of lacunar stroke performed within the first ten 
days shows evidence of cerebral infarction in 50-60%,^^^ the prognostic 
significance of a visible ischaemic lesion on CT is unclear. A number of recent 
studies have addressed the prognostic value of CT appearances following 
cerebral infarction of any size or !ocation^^®'^®° however only one^^® analysed the
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significance of an appropriately-placed visible ischaemic lesion on CT (as 
opposed to no visible lesion) in a small (n=258) subgroup of patients with lacunar 
symptoms, using a multiple logistic regression model to adjust for confounding 
baseline variables. We used prospectively-acquired data from a larger cohort to 
compare the outcome of lacunar stroke patients in whom CT scanning had 
revealed an appropriate ischaemic lesion with those lacunar stroke patients in 
whom no such lesion had been identified.
5.02 Subjects and Methods
The Acute Stroke Unit of the Western Infirmary in Glasgow serves a catchment 
population of 220,000. All patients who present within 72 hours of onset of acute 
neurological deficit with no known alternative to a vascular cause are admitted 
irrespective of age or severity of neurological deficit. Approximately 800 patients 
are admitted each year. All patients are classified using the Oxford Community 
Stroke Project^® classification, and brain imaging using either CT or MRl is 
performed within 72 hours o f admission on all patients with a clinical diagnosis of 
stroke. Prior to July 1994, a Phillips Tomoscan 310 CT scanner was used to 
perform computed tomography on stroke patients; subsequently a Phillips 
Tomoscan SR7000 has been used. A standard protocol has been consistently 
employed, taking 5mm slices through the brainstem and 10mm slices through 
the cerebral hemispheres. Clinical and radiological data from each patient are 
reviewed and verified by a neurologist, radiologist and stroke physicians before 
being recorded prospectively on a computer database.
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Using the database, we identified 633 patients who presented with symptoms 
consistent with lacunar stroke between June 1990 and February 1998. Of these 
patients, 114 were either imaged with CT at greater than 30 days following onset 
o f symptoms, or imaged with magnetic resonance; these patients were excluded 
from the analysis. Forty-one patients with intracranial haemorrhage or non- 
cerebrovascular lesions on GT were also excluded. Due to the insensitivity of x- 
ray computed tomography in the detection of early cerebral ischaemia, the 57
:patients in whom CT scans had been performed within 12 hours of onset of 
symptoms were not included in the analysis. A further 17 patients were excluded 
due to incomplete follow-up data.
The remaining 404 patients were divided into two groups, depending on the 
appearance of the CT scan. Patients with a low-attenuation area on the CT scan 
consistent with an ischaemic lesion in an appropriate region of brain to explain 
the presenting symptoms were classified as "CT positive". Patients with either a 
normal CT scan of brain or a scan which showed a lesion in an area inconsistent 
with the presenting symptoms were classified as “CT negative”.
A series of known or suspected prognostic factors were recorded for each 
patient: blood pressure (systolic, diastolic, and mean arterial), age, smoking, 
plasma glucose level, serum cholesterol level and serum triglyceride level. Delay 
from stroke onset to scanning was also noted.
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W e considered three outcome measures: survival time, outcome at 6 months 
after the stroke and total hospital length o f stay for the stroke admission. Six 
month outcome was categorised as good (alive at home) or poor (alive in care or 
dead).
5.03 Statistical Methods
Survival times in patients with and w ithout visible infarction on CT were 
compared using a log-rank test. A proportional hazards modeP'*® was then used 
to assess the effect o f visible infarction on survival after correcting for other 
clinical and biochemical factors known or suspected to influence prognosis.
A comparison of six-month outcome with respect to presence or absence of 
infarction on CT was performed using a chi-squared test. We then used 
stepwise logistic regression to adjust for significant prognostic factors before 
assessing the effect of CT findings on six-month outcome.
120
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aPatients were followed up for surviva* and subsequent hospital admissions using 
record linkage^"^^ to the national registers o f deaths and hospital discharge
records (SMR1). The technique of record linkage has been validated as a 
method o f endpoint detection in a large clinical t r i a l . R e c o r d  linkage is a 
reliable method: false positive and false negative linkage rates are approximately 
The method does not detect admissions to private hospitals or episodes 
o f care in institutions outside Scotland.
I
A Mann-Whitney test was used to compare median total length of hospital stay in 
patients with and without visible infarction on CT.
5.04 Results
W e identified 404 patients who had been admitted to the Acute Stroke Unit of 
the Western Infirmary vdth a clinical diagnosis of lacunar stroke and who met the 
other criteria detailed above. Of these, 142 (35.1%) were scanned between 12 
and 24 hours of onset of symptoms, 183 (45.3%) were scanned between one 
and three days of onset, and 79 (19.6%) were scanned between three days and 
thirty days after onset. Only seven of these patients were scanned at an interval 
of greater than 10 days after stroke onset: this delay was due to the CT scanner 
being broken. The mean elapsed time between onset of symptoms and CT scan 
was 2.7 days. Table 5.1 describes the clinical, radiological and biochemical 
features of the patient group.
Figure 5.1 shows the Kapian-Meier survival curves for CT positive and CT 
negative patients. There was no difference in survival between the two groups 
(p=0.29, log-rank test). After adjusting for other significant prognostic factors 
(age, p<0.0001; plasma glucose level, p=0.03) in a proportional hazards model, 
presence of visible infarction remained non-significant (p=0.40). Table 5.2 gives 
the results of the proportional hazards modelling.
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After adjustment for the other significant factor (age, p=0.0001), there was no 
significant difference in six month outcome between CT positive and CT negative 
patients (p=0.6T, see table 3). Median total length of hospital stay was not 
significantly different between the two groups (CT positive. 9 days; CT negative,
8 days; Mann-W hitney test, p=0.29).
5.05 D iscu ss io n
Our data suggest that following lacunar stroke, the presence of visible infarction 
on CT scan performed between twelve hours and thirty days of ictus is not 
predictive o f outcome or duration of hospital stay. This conclusion is consistent 
with other published work^®^’ ®^° however unlike these studies, our findings are 
based upon observations from a large cohort o f patients with correction for other 
factors known to predict outcome and long-term follow-up. A further study o f the 
prognostic significance of computed tomography findings following stroke in 
which a subgroup of patients with lacunar stroke was examined reached different 
conclusions.
In this previous study, a more complex multiple logistic regression model was 
used to investigate the prognostic effect of visible infarction in 258 patients with 
lacunar stroke, and the authors reported that visible infarction was an adverse 
prognostic indicator of borderline significance. Delay from onset of symptoms to 
CT scan was a significant prognostic factor. This was not the case in our study, 
since all patients were scanned according to our Acute Stroke Unit protocol and
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severity of deficit did not substantially influence the delay in scanning. Addition of 
the scan delay variable to any of the analyses presented here did not alter any of 
the results.
Other methodological differences between our study and that of W ardlaw et a!^ ®® 
are less likely to account for the difference in results. We used a less complex 
model with fewer prognostic variables, although in the subgroup of patients with 
lacunar symptoms parameters used in the previous study’s model such as 
diminution in conscious level and language disorder would not, by definition, 
have been of relevance. Our study used one radiologist to interpret the CT 
scans, unblinded to clinical data. The previous study used several similarly 
unblinded observers, however inter-observer variability in the interpretation of CT 
brain scans has been shown to be satisfactory.
A  further possible explanation for the disparity in results between the two studies 
lies in the assessment of the CT images. An association between infarct volume 
on CT scan and functional outcome in patients with lacunar and other stroke 
subtypes has been reported;^®® it is possible that the cruder dichotomisation of 
scan appearance into "present" or “absent” in both studies may have masked an 
underlying concordance in data.
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5,06 Conclusion
We conclude that in our cohort of patients, having corrected for other prognostic 
variables, the presence of visible infarction on CT brain scan performed between 
twelve hours and thirty days of onset of lacunar symptoms is not predictive of 
duration of hospital stay or of longer-term outcome.
Table 5.1 Characteristics of patients studied
n=404
Male sex 201 (49.8)
Infarct visible on CT scan 170 (42.0)
Current smoker 163 (41.7)
Delay (days from stroke onset to CT scan) 2 (1 to 3)
Age 71 (61 to 79)
Blood pressure
Systolic 160 (142 to 185)
Diastolic 90 (80 to 100)
Mean arterial 113 (102 to 127)
Plasma glucose level (mmol/lit) 6.0 (5.1 to 7.3)
Serum cholesterol level (mmol/lit) 5.7 (4.9 to 6.6)
Serum triglyceride level (mmol/lit) 1.4 (1.0 to 2.0)
For the variables sex, visible infarction and current smoker, data are presented 
as number of patients (percentage of patients). The remaining variables are 
described as median (interquartile range).
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Table 5.2 Results of proportional hazards modelling of survival
Variable Relative
hazard
95% confidence 
interval
p-value
Age (per decade) 1.67 1.37 to 2.02 <0.0001
Plasma glucose level (per mmol/l) 1.08 1.01 to 1.16 0.03
Infarction visible on CT 0.84 0.54 to 1.28 0.40
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Table 5.3 Six-month outcome: results of logistic regression analysis
V a ria b le Odds 95% confidence p-value
ratio interval
Age (per decade) 0.52 0.39 to 0.71 0.0001
Infarction visible on CT 1.19 0.63 to 2.23 0.61
Odds ratios refer to the odds of good (alive, at home) versus poor (alive in care 
or dead) outcome.
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Chapter Six
Diagnostic diffusion-weighted magnetic resonance imaging of acute
ischaemic stroke at 1.0 Tesla
■4.Ivt
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6.01 Introduction
Magnetic resonance imaging has long been used in the investigation of structural 
pathology of the brain. More recently, it has been used to investigate 
pathophysiological processes such as acute cerebral ischaemia. With the advent 
o f thrombolytic treatment for ischaemic stroke, the ability to image ischaemic 
brain tissue within the therapeutic time window of 180 minutes has become 
clinically advantageous.^®^ The accurate localisation and quantification of 
Ischaemic damage in the hyperacute phase of stroke may also permit more 
rational assessment of the effects of neuroprotective therapies. Conventional 
magnetic resonance sequences are unable reliably to identify ischaemic brain 
tissue within 6 hours of onset of acute ischaemic stroke.^®® Diffusion-weighted 
magnetic resonance imaging (DW-MRI) is highly sensitive to changes in the 
diffusion o f water molecules through tissue, such as those which occur In 
acutely-ischaemic brain. As discussed in chapter one, the signal intensity o f a 
tissue being imaged with magnetic resonance depends upon proton density, T 1, 
T2 and T2* relaxation processes of the spins within each imaging element or 
voxel. The random diffusion of protons within the tissue being studied will lead to 
random shifts in spin orientation and consequent loss of signal. The rate and 
direction o f proton diffusion are affected by molecular and macromolecular 
barriers to diffusion, hence water molecules within tissue travel approximately 
half of the distance travelled by free water molecules in the same time interval. 
The potential clinical application of diffusion-weighted imaging was realised when 
abnormal DW-MRI sequences in association with normal T1 and T2 weighted
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MRl studies were observed in the cat middle cerebral artery occlusion model 
within minutes of onset of i s c h a e m i a , i n  experimental models, reduction in 
cerebral blood flow to 15-20 ml/100g/minute is associated with a profound fall in 
the diffusibility of water through the ischaemic tissue, termed the apparent 
diffusion coefficient (ADC)/^^ This fail in ADC arises as a result of influx of water 
molecules through the membranes of ischaemic cells. Once trapped within 
ischaemic cells, the diffusion of water molecules is slowed and restricted. Clinical 
studies^^®*^^® have confirmed the ability of this technique to identify early 
ischaemic cerebral damage in stroke patients before any abnormalities are seen 
with conventional imaging techniques such as x-ray computed tomography or 
T2-weighted magnetic resonance scanning.
As DW-MRI is sensitive to the Brownian motion of water molecules within brain
tissue, the technique is highly susceptible to macroscopic patient movement 
artefact. Severe image distortion may arise as a result of voluntary or involuntary 
patient head movement, breathing motion, and brain and CSF pulsation as a 
result of cardiac systole. Large-scale movement of the tissue under examination 
causes severe "ghosting” artefact in the image which often renders it difficult to 
interpret. The two main methods of compensation for patient movement are the 
use of navigator e c h o e s ^ t o  correct for movement, or rapid image acquisition 
with echo-planar techniques. Navigator echoes involve the addition of an extra 
spin echo to the sequence, which enables motion-induced phase variations to be 
identified and corrected. Cardiac gating is also used to reduce image distortion
Î
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arising from brain pulsation further. Although successful, the use of navigator 
echoes requires extensive image cost-processing which significantly prolongs 
overall scan time and hence detracts from the usefulness of the technique in the 
context of acute stroke. With improved hardware, distortion due to patient 
movement can be reduced by obtaining the images in less than one second 
using Echo-Planar Imaging This technique uses rapid gradient
pulses to produce an image within 100 ms. Although EPI allows rapid image 
acquisition, image quality is often compromised by distortion artefacts that occur 
at boundaries of regions with differing magnetic resonance characteristics, such 
as air-tissue interfaces. As a result of this distortion, areas of brain adjacent to 
the sinuses are often very poorly visualised during echo-planar imaging. Only 
with machines at field strengths of at least 1.5 T have the manufacturers made 
concerted efforts to resolve these distortions. Hence to date the implementation 
of DW-MRI has been hindered and restricted to major centres and optimised 
research sites. Therefore, in a centre with a 1.0 T magnet an alternative 
approach to EPI is required. To attempt to overcome this difficulty we reverted to 
a compromise between acquisition time and image quality, the use of a time- 
reversed steady state sequence (given the acronym "PSIF" as it is a reversed 
form o f the fast imaging with steady-state precession or “FISP” sequence) which 
had previously been used at high (1.5 T) magnetic field s t r e n g t h . W e  
developed the sequence further and optimised it for use on our standard 1.0 
Tesla scanner. The partial flip angle and low repetition time used by the PSIF 
sequence enables the stimulated echo (or “left-over”) component of the signal to
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be detected and used to generate an i m a g e . T h e  application of a diffusion 
gradient during each repetition allows a heavily diffusion-weighted stimulated 
echo to be measured. A graphical representation of the pulse sequence timing 
diagram is shown in figure 6.1. We sought to investigate the clinical utility of such 
a sequence at 1.0 T in the investigation of patients with ischaemic stroke.
6.02 Methods 
Patients
The Acute Stroke Unit o f the Western Infirmary in Glasgow serves a catchment 
population of 220,000. All patients who present within 72 hours of onset of acute 
neurological deficit with no known alternative to a vascular cause are admitted, 
irrespective of age or o f severity of neurological deficit. Patients are classified 
using the Oxford Community Stroke Project^® classification. Between June and 
September 1998, consecutive patients presenting to the Acute Stroke Unit with a 
provisional diagnosis of stroke within 8 hours of onset of neurological deficit and 
with no contra-indications to MR scanning underwent both conventional and 
diffusion-weighted magnetic resonance imaging. A full explanation of the 
procedure was given to each patient and verbal consent was obtained prior to 
imaging.
imaging Protocol
A Siemens 1.0 T Impact Expert Scanner was used with a PSIF based diffusion 
weighted sequence programmed using the Pargen Sequence Editor.
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Parameters were:
Repetition Time 29 ms Echo Time 9 ms Flip Angle 50°
Field of View 240 mm Slice Thickness 6 mm.
A strong diffusion gradient of 16.5 mTm'^ was applied for 7 ms. A weak gradient 
of 3 mTm "1 was also used.
Five acquisitions were taken to ensure good signal-to-noise in the image and to 
minimise any remaining artefact.
Diffusion weighted imaging was performed by taking transverse sections through 
the head to determine the possible location of an acute stroke. On definite 
depiction of the stroke area, strong diffusion weighted imaging was repeated in 
the other two gradient directions.
Baseline images using a very weak diffusion weighting setting were also
acquired for comparative purposes. All images were reviewed at the time of 
acquisition by a consultant radiologist. The addition of the DW sequence to the 
conventional series of sequences prolonged overall scan time by approximately 
ten minutes.
6.03 Results
I
Sequence optimisation
A standard water phantom was used to optimise the DW-PSIF sequence. 
Optimisation was achieved by increasing the diffusion gradient amplitude and
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limiting the repetition time. If the repetition time is increased then the scan time 
will increase, and as a result the images will be more susceptible to patient 
movement artefact. If the diffusion gradient is increased then the images will also 
be more susceptible to patient movement artefact as the scan will become more 
sensitive to tiny movements.
The signal (S) measured in the presence of the diffusion gradient can be 
described as
S= So e(-bD*)
W here So is the signal intensity in the absence of a diffusion gradient, D* is the 
apparent diffusion coefficient of the tissue and b is a measure of the diffusion 
sensitivity.
The diffusion sensitivity, b, is proportional to the square of the gradient strength, 
although it is also dependent on the type of diffusion sequence used.
W hen the natural log of (S/So) is plotted as a function of the b value, the slope of 
the resultant line is -bD . Determination of the b value of a diffusion-weighted 
PSIF sequence is mathematically complex, as the stimulated echo component of 
the signal is used to generate the image. The natural log of S/So was plotted 
against the square of the gradient strength, and the gradient of (b/k)D was found 
to be -0 .00423 (figure 6.2) fo r the original sequence, and -0.0078 (figure 6.3) for 
the optimised sequence. (In this calculation, k represents the constant necessary
• i : :
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to adjust fo r the use of a stimulated echo sequence.) The optimisation process 
had therefore increased the sensitivity of the sequence by a factor of 1.84,
Using a standard echo-planar diffusion-weighted sequence with a known b value 
of 1000 and a standard water phantom, a calibration experiment was performed. 
The natural log of S/So using the echo-planar sequence was -2.26; the 
optimised PSIF sequence yielded a value o f -2 .3  when the same phantom was 
used. The diffusion sensitivity of the optimised PSIF sequence was therefore 
calculated to be 1025 s/mm^. The relative gradients of the original and optimised 
sequences are shown in Figure 6.4.
Clinical application
10 patients (8 male, 2 female) were scanned. Median age was 66.5 years (range
50-83 years), median NIH score on presentation was 5 (range 1-16). 2 patients 
had symptoms and signs consistent with total anterior circulation stroke, 3 had 
partial anterior circulation stroke, 2 patient with lacunar symptoms and 2 patients 
had posterior circulation stroke. One patient with transient global amnesia was 
scanned at 6 hours after onset of symptoms.
All patients were scanned within 8 hours of onset of neurological deficit. Median 
elapsed time between onset and scan was 5 hours 55 minutes (range 2 hours 35 
minutes to 7 hours 10 minutes). Clinical and radiological findings are 
summarised in table 6.1. Evidence of cerebral ischaemia was seen as an area of
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signal hyperintensity in the DW-MRI sequences of all patients scanned. In 5 
patients, corresponding T2-weighted MRÎ sequences revealed no overt 
abnormality. In these cases, the abnormal diffusion-weighted image provided 
strong radiological evidence to support a diagnosis of ischaemic stroke. In two of 
these five cases (patients 6 and 10) a differential diagnosis of migraine had been 
considered as a cause for their symptoms (right hemiparesis and right-sided 
visual disturbance respectively). The abnormal diffusion-weighted images 
allowed exclusion of this possibility and influenced early management. Figure 6.5 
shows the images acquired from patient 10,
In cases 5 and 8 (figure 6.6), evidence of previous cerebral infarction was 
apparent on T2-weighted MR! sequences. The images from patient 8 are shown 
in figure 6.6. As diffusion-weighted images are sensitive only to recent ischaemic 
lesions, the DW! sequence in these patients allowed differentiation of old lesions 
from new areas of cerebral ischaemia. The cause of a further episode o f focal 
neurological disturbance in patients with previous stroke is often elusive. Such 
patients are at increased risk of further cerebrovascular events, however they 
may also be prone to seizure activity as a result of previous cerebral injury. In 
order to provide appropriate therapy, it is important to be able to distinguish 
these two causes. Diffusion-weighted imaging allowed positive identification of a 
new cerebral ischaemic lesion in these patients, and management was 
influenced accordingly.
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In patient 1, tiny parietal lesions were seen on the diffusion-weighted images, 
which did not register on the T2-weighted sequence. The spatial resolution of the 
PSIF sequence enabled these lesions to be visualised; it is notable that the 
coarser matrix used by many echo-planar diffusion weighted sequences would 
not reliably detect such lesions. Figure 6.7a shows the diffusion-weighted PSIF 
image, figure 6.7b shows the same image when displayed using a coarser 
matrix, typical of EPI images from a 1,5T scanner.
Repeat imaging at an interval of one month was performed in three patients, in 
each case established cerebral infarction was seen in the area identified by the 
DW sequence. Early and interval images from patient 7 are given in figure 6.8. A 
lesion in the subcortical area of the left parietal lobe was demonstrated on the 
early diffusion-weighted image; interval imaging with CT confirmed established 
cerebral infarction involving this area.
6.04 Discussion
Diffusion-weighted MR! has the potential to be widely applied in both clinical and 
research environments. Recent trials of thrombolytic therapy for acute ischaemic 
stroke have emphasised the difficulties in the interpretation of CT imaging 
acutely following s t r o k e . D i f f u s i o n - w e i g h t e d  magnetic resonance imaging 
will enable early, accurate diagnosis, quantification and topographical 
localisation of early ischaemic stroke. It has been proposed that, in combination 
with perfusion imaging, diffusion-weighted MRI may represent a more sensitive
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tool for identifying patients most likely to respond to thrombolytic t h e r a p y , a n d  
one early study appears to suoport that hypothesis.^®®
Diffusion-weighted MRI also has potential application in the development of 
novel neuroprotective therapies. As the clinical course of stroke is highly 
variable, efficacy studies using clinical endpoints require large numbers of 
recruits to demonstrate an effect. As neuroprotective therapy should reduce the 
size of the eventual damage to the brain, the ability to assess changes in infarct 
volume over time using both DW-MRl and T2-weighted imaging may become a 
rational useful surrogate endpoint in the evaluation of new drugs. As the 
pathophysiology of white matter ischaemia differs from that of cortical ischaemia, 
it may be that pharmacologically different agents will be required to treat 
ischaemic stroke, depending upon the area of brain affected. Accurate, early 
localisation of cerebral ischaemia will be necessary to enable administration of 
the appropriate drug.
The high field-strength scanners required for diffusion-weighted imaging are not 
w idely available in the UK centres where patients with stroke are routinely 
managed. Our aim in this study was to develop and validate a diffusion-weighted 
MRI sequence which operates using a conventional MRI scanner and hence has 
the potential to expand the availability of diffusion-weighted imaging. Due to the 
pragmatic nature of the study, we did not attempt to quantify restricted diffusion 
by calculating apparent diffusion coefficient (ADC), nor did we generate ADC
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maps. Although theoretically possible using our s e q u e n c e , A D C  map
generation would have significantly increased the duration of the scan.
6.05 Conclusion
In conclusion, we have found that clinically useful DW-MRI imaging of acute 
ischaemic stroke is possible using a 1.0 T scanner without EPI. Although 
analysis of ADC values has been shown to provide additional information 
particularly on the age of the l e s i o n , w e  have found that omission of ADC 
calculation does not significantly detract from the clinical utility of the sequence. 
Recent literature has confirmed the robust and reliable nature of diffusion- 
weighted MRI in the characterisation of early cerebral ischaemia.^®®'^®'^ A strong 
case for the use of magnetic resonance (including diffusion-weighted MR) as the 
principal imaging modality for initial investigation of the acute stroke syndrome is 
emerging, and on the basis of accumulating evidence more widespread 
implementation of diffusion MR has been proposed.
The ability to perform DW-MRI on a 1.0 T scanner should enhance the 
applicability of the technique, and improve the ability of centres with conventional 
MRI scanners to investigate patients with acute ischaemic stroke.
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Tabie 6.1 Patient Characteristics
Number Age/Sex Delay OCSP T2 MR DW MR
1 51 M 5'45 L PACS Scattered subcortical high signal L parietal infarct
2 73 M 4’OG LPOCS Normal L pontine infarct
3 58 M 6’GO TGA Normal L medial temporal high signal
4 81 F 6’1G LPACS Atrophy. Nil focal L parietal infarct
5 53 M 5’00 LLACS Old R pontine infarct New L subcortical infarct
6 66 M 6’30 LLACS Normal L subcortical infarct
7 67 M 2’35 LTACS Normal L parietal infarct
8 83 F 7’10 LTACS Extensive infarction L cerebral hemisphere New L subcortical infarct
9 82 M 6 1 5 LPACS Diffuse small vessel disease. Nil focal L frontoparietal infarct
10 50 M 4 ’45 LPOCS Normal L occipital Infarct
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Figure 6.1 Pulse sequence timing diagram of the PSIF sequence.
This diagram illustrates the timing of introduction of the radiofrequency pulse (top 
line) and subsequent application of magnetic gradients in each of the three 
orthogonal planes (phase, read and slice).
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Figure 6.2 Calculation of b value of original sequence.
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Figure 6.3 Calculation of b value of optimised sequence.
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Figure 6,4 Comparison of gradients of original and optimised sequences.
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Legends to Figures
Figure  6.5a T2 Weighted scan of 50 year-old man with right homonymous 
hemianopia of 7 hours' duration.
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Figure  6.5b Diffusion weighted image of same patient taken several minutes 
earlier.
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Figure 6.6a T2 W eighted scan of 83 year-old woman with sudden deterioration
in longstanding right limb weakness.
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F igure  6.6b Diffusion-weighted scan of the same patient taken at the same 
time. The new left subcortical lesion is demonstrated.
148
M iTr
Figures 6.7a and 6.7b Diffusion weighted images of a 51 year-old man with 
right hemiparesis and a language disorder, demonstrating tiny cortical and 
subcortical areas of abnormally high signal, which are not seen when a coarser 
(EPI) matrix is used.
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Figure 6.8a Diffusion-weighted scan of a 67 year old man with language
disorder, right limb weakness and right visual field deficit.
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Figure 6.8b interval CT scan of same patient showing established left 
hemispheric cerebral infarct.
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Chapter Seven
Intravenous thrombolysis in acute ischaemic stroke: 
preliminary experience with rt-PA in a UK hospital
;52
7.01 Introduction
The National Institute of Neurological Disorders and Stroke (NINDS) trial 
evaluated 624 patients with acute stroke. 0.9 mg/kg recombinant tissue 
plasminogen activator (rt-PA) or placebo was administered within 3 hours of 
onset of stroke symptoms. All patients underwent emergency CT scanning 
before administration of rt-PA and half the patients were treated within 90 
minutes. Patients treated with rt-PA were 30% more likely to have minimal or 
no disability at three months than those given placebo. This improvement in 
outcome occurred despite a 10 fold increase in the rate of symptomatic 
intracerebral haemorrhage (6.4% vs 0.6%). Even with this higher rate of 
secondary haemorrhage mortality was similar in the two groups (17% in the 
thrombolysed group vs 21% in the placebo group).
The European Cooperative Acute Stroke Study (ECASS) study randomised
patients to a higher dose of 1.1 mg/kg rt-PA or placebo within a longer time 
window (6 hours of stroke). There was no improvement in functional outcome 
in the intention to treat analysis but reanalysis after exclusion of a large 
number of ineligible patients from the target population suggested a significant 
improvement in functional outcome in rt-PA receiving patients (P = 0.035).^°^ 
A further ECASS trial, assessing the lower dose of rt-PA used in NINDS and a 
6 hour time window failed to show significant benefit when pre-specified end 
points were examined; the trial has been interpreted as neutral.
15:
Earlier studies evaluating streptokinase (SK) therapy reported negative results 
with a high frequency of complicating cerebral haemorrhages and a resultant
increase in ear'/ mortality in the treated groups.
The only clearly favourable trial of thrombolysis in acute ischaemic stroke was 
the NINDS study; however meta-analysis of the use of thrombolysis in this 
context has shown consistent benefit from rt-PA and no benefit from 
streptokinase.^^
On the basis of the NINDS study results, rt-PA is licensed for the treatment of 
ischaemic stroke in the United States. It is currently used outwith license in 
Europe for the same indication. Concerns over the safety and practicability of 
this treatment when employed outwith US centres have been raised, due to 
differences in the provision of acute stroke services between Europe and 
North America.
7.02 Subjects and Methods
The acute stroke unit of the Western Infirmary in Glasgow serves an urban 
catchment population of 220,000. Patients with symptoms and signs 
consistent with a clinical diagnosis of stroke are admitted regardless of age or 
seventy of neurological deficit, amounting to approximately 800 patients per 
year. Thrombolysis has been used selectively within the unit since 1996. We 
report a consecutive, prospectively evaluated series of patients with acute 
ischaemic stroke treated with rt-PA.
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■'Between April 1996 and November 1998, rt-PA was administered on sixteen
Clinical and Imaging Protocol
occasions to fifteen patients. Thrombolytic therapy was only given after 
discussion with a consultant stroke physician. Eligibility criteria were according 
to the entry criteria of the NINDS study and the American Heart Association 
g u id e l in e s , i.e. administration of treatment within three hours of onset of 
symptoms following a normal CT scan. In general, patients were excluded if 
they were at risk of haemorrhage, (for example bleeding diathesis, active 
gastro-intestinal ulceration or recent surgery), if the focal neurological signs 
were attributable to metabolic disturbance or seizure activity, or if the deficit 
was rapidly resolving. Although the NINDS blood pressure criteria were 
a p p lie d ,in te rve n tio n  to reduce blood pressure in order to meet American 
Heart Association guidelines was not undertaken. Our patients are therefore 
likely to have a higher blood pressure than patients entering the NINDS trial.
g
:
I
Clinical and radiological data were prospectively recorded. Neurological and 
functional deficit were classified at admission according to the Oxford
Community Stroke Project subtype^® and NIH Stroke Sc a le .P a t i en t s  were 
reviewed at three months using the Rankin score and Barthel index. The 
reliability and reproducibility of these measures have been confirmed
previously.^®'”*®^
I
Patients who were potentially eligible to receive thrombolytic therapy 
underwent emergency brain CT. Twenty four hour access to CT scanning was
155
available, and following discussion with the radiology department, potential 
suitability for treatment with rt-PA was classified as an indication for 
emergency CT brain scan. All scans were reported by a consultant or senior 
registrar in radiology at the time of scanning. If there were no signs of major 
cerebral infarction or haemorrhage 0.9 mg/kg intravenous rt-PA was 
administered following an informed discussion amongst senior medical staff, 
patients and other family in attendance. 10% of the total dose was given as a 
bolus and the remainder infused over 60 minutes.
Heparin was co-prescribed in one patient with severe carotid disease and a 
fluctuating neurological deficit; otherwise no patient received concomitant 
anticoagulant therapy. Antiplatelet therapy was disallowed for 24 hours after 
administration of rt-PA. All but one patient (who was scanned 7 days post 
thrombolysis) underwent follow up CT scanning between 48 and 72 hours, to 
evaluate the frequency o f haemorrhagic transformation.
Patients received routine clinical care from the medical and nursing staff of the 
acute stroke unit. Death, new stroke, significant systemic bleeding and 
intracranial haemorrhage were monitored as primary adverse events. An 
intracerebral haemorrhage was considered to be symptomatic only if it was 
associated with a deterioration in neurological status.
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7.03 R esu lts
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Patient demographics and clinical details are summarised in Table 7.1. The
mean elapsed time from onset of deficit to start of thrombolytic infusion was 
141 minutes (SD 42).
■T-'T
All patients received appropriate bolus and infusion doses of rt-PA. No 
symptomatic intracranial haemorrhages were reported. One clinically-silent 
haemorrhagic transformation of left middle cerebral artery infarction was 
detected on a follow-up scan three days after treatment.
Of nine patients with total anterior circulation stroke, three were Independently ■g
living at home three months after presentation, three were alive and 
dependent and three had died. In total, five patients were independently living
"at home and a further two patients were living at home with support. Five 
patients were significantly disabled and dependent, either in hospital or in
nursing home care. Outcome at three months as measured by NIH score and
■
Barthel index Is shown in figure 7.1 and 7.2, along with the NIH scores and 
Barthel indices of participants in the second part of the NINDS trial for 
comparison. Also shown for comparison are the reported results^®® of a 
German acute stroke unit.
s
Four patients died following treatment with rt-PA. Two deaths were attributed
to massive cerebral infarction complicated by cerebral oedema, and two to 
hypostatic bronchopneumonia.
I
Patient 3 made a full recovery from a left lacunar syndrome following
infarction.
later.
Patient 6 developed left hemispheric total anterior circulation infarction whilst 
being treated in hospital for pneumonia. She was treated with rt-PA 100 
minutes after onset of symptoms. No change in neurological status was 
observed immediately following dosing. Conscious level deteriorated the 
following day, and repeat CT scan performed 36 hours after onset of 
symptoms revealed massive left hemispheric infarction with significant mass
thrombolysis and underwent left carotid endarterectomy for a high-grade
symptomatic carotid stenosis three days later. He developed a posterior 
circulation stroke within 10 days of carotid endarterectomy and was treated 
with a second infusion of rt-PA. Follow up CT scan revealed a new pontine
1 
f
Patient 4 presented with a dominant hemisphere total anterior circulation 
infarction having undergone uncomplicated coronary angiography one week 
before. Initial CT showed no abnormality. Following administration of rt-PA, 
he developed an extensive groin haematoma over the site of the arterial 
puncture. No change in focal neurological signs occurred immediately 
following administration of rt-PA; however 30 hours following thrombolysis, 
conscious level deteriorated and signs consistent with brainstem compression 
were observed. Repeat CT scan revealed an extensive left hemispheric
.■,/i.
infarction with evidence of cerebral oedema and the patient died three days
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effect. Her conscious level deteriorated progressively and she died two weeks 
after onset of symptoms.
7.04 D iscussion
Few patients referred to the acute stroke team are assessed and CT scanned 
by 180 minutes of onset of symptoms. The delays in presentation to hospital, 
CT scanning and reconstitution and administration of thrombolytic drug are 
summarised in figure 7.3. It is significant that three patients in this series were 
already in hospital at the time of stroke. Figure 7.4 illustrates the pattern of 
delay in presentation to hospital in a series of 200 consecutive patients 
referred to the Acute Stroke Unit between April and July 1998. In most cases 
delay is due to procrastination in contacting the primary care team or delay in 
GP referral to hospital. In our local area since March 1998, patients with 
symptoms consistent with stroke of less than three hours' duration have been 
afforded highest priority by the local ambulance service and are now brought 
directly to hospital as an emergency.
Failure in the early identification of stroke may also occur because of a lack of 
awareness on behalf of the patient or their relatives. Increased awareness of 
symptoms and the perception of stroke as a medical emergency may be 
achieved through educational campaigns directed at “at risk” populations. The 
accurate identification of a well-defined time of onset is a prerequisite for the 
safe use of thrombolytic therapy. Failure of the patient or clinician to identify
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pre-existing subtle neurological symptoms which suddenly worsened may lead 
to inappropriate use of rt-PA.
A further consideration is the means through which medical attention is 
sought. Approximately 50% of admissions to our unit are referred by local 
general practitioners, in areas where the emergency services treat stroke with 
the same priority as acute myocardial infarction, it has been shown that 
admission to hospital is significantly more rapid. This often bypasses the 
primary care physician; instead the emergency paramedical services are the 
initial point of patient contact.
Once within the hospital, the narrow therapeutic time window demands rapid 
and accurate assessment by medical staff. The presence of a dedicated
“stroke team” with access to emergency 24 hour on site CT scanning are 
prerequisites for thrombolytic stroke therapy. It is therefore likely that this 
treatment could only be offered at specialist centres.
It is vital that the outcome in patients receiving unlicensed thrombolytic 
therapy be continuously audited, to ensure patients are not being exposed to 
unacceptable risk. Baseline median NIH scores in both the placebo and 
treated cohorts of the NINDS study were significantly lower (14) than those 
patients treated in Glasgow (19).”'°^ In other words our stroke population were 
more severely affected than those typically recruited to the NINDS study. The 
medical staff involved currently only consider thrombolytic therapy in those
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7.05 Conclusions
rt-PA is currently licensed for the treatment of acute ischaemic stroke in the 
US. Limited approval for its use in the Europe is under consideration. This 
may depend on the interpretation of results of recently completed clinical 
trials, such as ECASS if^® Although the ECASS II trial was interpreted as 
neutral, incorporation of its data into a meta-analysis of trials of rt-PA within 3 
hours of onset of acute stroke reveals a favourable odds ratio of 0.67 (95% Cl 
0.56 - 0.80) with respect to death and disability.^^^'^"^^
Although many clinical and logistical difficulties complicate its use, our patient 
outcome and complication rate are in keeping with those of the NINDS
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patients with severe stroke, conscious of adversely affecting patients who 
might otherwise have a good prognosis. In contrast to the NINDS study, no 
treatment to lower blood pressure acutely following ischaemic stroke is 
undertaken in patients eligible to receive thrombolytic therapy. Patients with 
total anterior circulation syndromes have a poorer prognosis than many forms 
of cancer i.e. 95% death or dependency at 6 m o n t h s . D e s p i t e  the relative 
severity of patients treated the outcome was satisfactory in comparison with 
that expected of untreated patients with similar degrees of disability at 
presentation. Figure 7.5 compares the three month functional status of 
thrombolysed patients with total anterior circulation infarction with interval 
outcome data from the untreated OCSP cohort.^® A trend towards improved 
functional outcome in these severely-affected patients is apparent although 
formal analysis of efficacy is not possible given the small numbers Involved.
investigators, while the small numbers involved preclude formal statistical 
analysis. We conclude that the judicious use of this treatment within a 
specialist unit appears safe, but requires careful continued audit. Substantive 
changes in the public and primary care providers’ perception of stroke as a 
medical emergency will be required before this treatment is more widely 
applied.
I
1
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Table 7.1 Patient Characteristics
Age/
Sex
OCSP NIH
Pre
NIH
Day 3
CT Post Rankin 
Month 3
Status 
Month 3
77 M TACS 23 1 Small Infarct 1 Home
69 F PACS 15 3 Small Infarct 1 Home
89 M LACS 14 13 Subcort. Infarct 4 Hospital
89 M POCS 23 18 Pontine Infarct 4 Hospital
64 M TACS 19 — Large Infarct Died day 2
85 F TACS 30 9 Small Infarct 2 Home
93 F TACS 25 24 Large Infarct — Died day 10
72 F TACS 21 8 Small Infarct 3 Home
59 M PACS a 0 Normal 1 Home
80 F TACS 25 22 Small Infarct 4 Hospital
84 M PACS 14 12 Large Infarct Died week 6
60 M POCS 5 1 Small Infarct 1 Home
70 M LACS 6 5 Small Infarct 2 Home
63 M TACS 19 23 Large Infarct •—* Died week 5
58 M TACS 25 23 Large Infarct 3 Hospital
87 F TACS 20 19 Silent Haem. Trans. 4 Nursing home
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Chapter Eight
Discussion of results and future directions
.64
8.01 Introduction
The underlying theme of the work presented in this thesis has been prognosis 
following stroke, and how it may be influenced or predicted. Three 
approaches to this theme have been adopted. I have sought to identify 
potential prognostic factors after stroke, such as serum triglyceride 
concentration and computed tomography appearances; to demonstrate in 
selected populations the safety and practicality of simple and potentially 
beneficial interventions such as control of blood glucose and blood pressure; 
and to implement novel techniques such as thrombolysis and diffusion- 
weighted magnetic resonance imaging of hyperacute stroke in the setting of a 
U.K. hospital. This chapter will provide a synopsis of the results of each study, 
together with a discussion of potential future research.
8.02 ACE Inhibition and Cerebral Perfusion
In chapter two the effect of the angiotensin converting enzyme inhibitor
...I
i
perindopril upon cerebral and renal perfusion in moderately-hypertensive 
stroke patients with extracranial carotid artery disease was investigated. 1 
hypothesised that perindopril would reduce blood pressure without 
significantly affecting cerebral perfusion. Using transcranial Doppler 
ultrasound, carotid Doppler ultrasound, dynamic HMPAO bolus imaging and 
single photon emission computed tomography, global and focal cerebral 
perfusion were assessed. No significant change in global or peri-infarct 
cerebral perfusion was observed in the treated group. There was no drug- 
associated neurological deterioration, however an episode of acute renal
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failure occurred in one of the treated patients; this was attributed to pre­
existing bilateral renal artery stenosis.
The cerebral perfusion data were consistent with those data acquired from a 
sim ilar study which examined the effect of ACE inhibition upon cerebral
perfusion early after ischaemic stroke.^®® The mechanistic basis of effect of 
ACE inhibition upon cerebral perfusion remains elusive. In rats, angiotensin II 
receptors are known to be involved in the regulation of cerebral perfusion^ 
and it is likely that a similar mechanism is implicated in humans. The study 
was not designed to examine the effect of blood pressure reduction with ACE 
inhibitors upon long-term outcome, and the cohort of patients studies had 
relatively mild degree of neurological impairment relative to an unselected 
cohort o f stroke survivors, hence no conclusions concerning longer-term 
outcome can be drawn. A large-scale study is currently undenway to 
investigate the potential effect of angiotensin converting enzyme inhibition on 
secondary incidence of stroke. Although the cerebral perfusion data are
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There was a degree of heterogeneity in the age, size and location of the index 
cerebral infarction of the patients recruited into the study. The degree and 
extent of the carotid artery disease was also variable. Given the possible 
permutations of carotid artery disease severity and extent of cerebral 
infarction, recruitment of an entirely homogenous group of patients is 
impracticable however further studies may be required to fully elucidate the 
effect o f ACE inhibition on cerebral perfusion in specific subtypes of cerebral 
infarction.
• '
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consistent with our original hypothesis, the episode of reversible acute renal 
failure observed In one treated patient raises some concern. It is known that 
patients with severe renal artery disease are significantly more likely to have 
extracranial carotid atheroma,”'^ ® however the prevalence of significant renal 
artery disease among patients with extracranial carotid artery atheroma is 
unknown. We conclude that intervention with ACE inhibitors will lower blood 
pressure in this population without adversely affecting cerebral perfusion, but 
that simple, validated non-invasive screening for the presence of renal artery
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stenosis (such as scintigraphy) should be considered prior to introduction of 
therapy.
I
8.03 Control of Hyperglycaemia after Ischaemic Stroke
Chapter three reported the results of a pilot study designed to investigate the 
safety and feasibility of rigorous glycaemic control early after ischaemic stroke
in patients with moderate hyperglycaemia. The deleterious effect of 
hyperglycaemia following experimental stroke has been extensively studied, 
73,124-128 clinical evidence to support a similar adverse effect in stroke 
patients has been pubtished.^®'^^®'”'®® In animal models, intervention with 
insulin following hyperglycaemic stroke reduces infarct volume and improves 
functional outcome.®'* Twenty-four hyperglycaemic patients with acute stroke 
were randomised to receive either standard management of blood sugar or 
rigorous control using insulin infusion titrated In accordance with a sliding 
scale. The ability of the sliding-scale insulin regime to maintain blood glucose 
concentrations in the pre-specified range was demonstrated. Symptoms 
consistent with hypoglycaemia were observed one occasion; these were
t .
minor and reversed rapidly following administration of oral dextrose. The 
purpose of the study was to investigate the feasibility and safety of one 
method of glycaemic control following acute ischaemic stroke; no conclusions 
concerning efficacy can be drawn as the study was not powered to 
demonstrate an effect upon outcome. Data acquired during this study may 
however be useful in the preparation of power calculations for future studies. I 
conclude that a larger trial is now warranted to investigate this. The pilot study 
has demonstrated the feasibility of the protocol used, however alternative 
means of glycaemic control such as the glucose-potassium-insulin (“GKI”) 
regime have also been employed in the context of hyperglycaemic ischaemic 
stroke p a t i e n t s . T h e  GKI regime is simple and easy to administer, but is 
less flexible as the relative rates of insulin and dextrose infusion cannot be 
varied independently of each other. A further study to compare the relative 
merits of these two approaches may permit the design of a definitive large- 
scale study to be optimised.
8.04 The Prognostic Significance of Triglyceride Concentration
Chapter four reports a long-term follow-up study designed to investigate the 
influence of serum triglyceride concentration upon outcome after stroke. An 
earlier study^^® had suggested an unexpected association between relatively 
high levels of cholesterol and better outcome following stroke. We sought to 
clarify the relationship between lipid concentration and stroke prognosis. 
Using the database maintained by the acute stroke unit of the Western 
Infirmary, 1312 non-diabetic patients presenting with computed tomography- 
confirmed acute stroke were identified. Data from fasting blood samples
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drawn within 24 hours of admission for glucose, lipids and a standard battery 
of biochemical and hematological tests were analysed. Information on age, 
stroke type, admission blood pressure, smoking status, presence of atrial 
fibrillation, resolution time of symptoms and Oxfordshire Community Stroke 
Project^® clinical classification was collated and incorporated into stepwise 
proportional hazards regression analysis to estimate the effect of these
parameters on survival following stroke. ■ Ï
The results obtained suggest that triglyceride concentration is associated 
independently with survival of patients with acute stroke; those with relatively
high triglyceride concentrations enjoyed a better prognosis than those with 
lower levels. Triglyceride concentration was found to be a better predictor of 
outcome than cholesterol.
The results presented raise a number of insights into the potential biological 
mechanisms underlying the relationship between lipids and stroke. The 
association of low triglyceride with relatively poor outcome following acute 
stroke suggests that there is no confounding effect of the inflammatory 
response as it is known that, in contrast with cholesterol concentration, 
triglyceride concentration does not fluctuate to a significant degree in the first 
week following ischaemic s t r o k e . T h e  median fasting total serum 
triglyceride concentration in our cohort was 1.3 mmoi/L. At this concentration, 
the majority of measured triglyceride circulates as very low density lipoprotein 
particles (VLDL). The results suggest that it is VLDL concentration which is 
predictive of stroke outcome, rather than concentration of other lipoprotein
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particles. As VLDL particles also carry cholesterol, the previously-noted 
relationship between cholesterol concentration and stroke outcome is also
consistent with this hypothesis. Further studies involving more detailed lipid 
analysis would be required for confirmation. All blood samples drawn were
analysed in the fasting state within 24 hours of admission to the hospital, 
hence any confounding effect of stroke-induced dysphagia is unlikely. Pre­
existing nutritional deficiency may account for the observed relationship 
between low triglyceride concentration and poor outcome; low serum 
triglyceride is a more sensitive indicator of poor nutritional status than low 
cholesterol conce n t ra t i on ,an d  patients with poor pre-stroke nutritional 
status may be less likely to enjoy a good outcome. A further prospective study 
using more detailed biochemical and anthropometric indices would be 
required to address this issue more fully.
8.05 Visible infarction after Lacunar Stroke
In chapter five the prognostic significance of appropriate visible cerebral 
infarction on x-ray computed tomography (CT) in patients with a clinical 
diagnosis of lacunar stroke is considered. Relatively few prognostic factors 
have been identified in this sub-group of stroke patients, and I sought to 
investigate whether patients with lacunar symptoms and visible infarction on 
CT had a poorer prognosis than those patients with similar symptoms and no 
appropriate CT lesion.
The computer database maintained by the Acute Stroke Unit of the Western 
Infirmary holds prospectively-acquired clinical, biochemical, radiological and
170
outcome data for all patients admitted to the unit. Using the database, we 
identified 633 patients admitted with lacunar stroke between 1990 and 1998. 
A total of 229 patients were excluded from the analysis due to incomplete 
follow-up, non ischaemic pathology or brain imaging other than CT. The 
remaining 404 patients were divided into two groups, depending on the 
appearance of the CT scan. Patients with an appropriately placed infarct on 
the CT scan classified as “CT positive". Those without such a lesion on the 
scan were classified as “CT negative”.
A log-rank test was used to compare survival times in patients with and 
without visible infarction on CT; then effect of visible infarction on survival 
after correcting for other prognostic factors was examined using a proportional 
hazards model.
A comparison of six-month outcome with respect to presence or absence of 
infarction on CT was performed using a chi-squared test. Stepwise logistic 
regression was then used to adjust for significant prognostic factors before 
assessing the effect of CT findings on outcome at six months. Length of 
hospital stay in each group was compared using a Mann-Whitney test.
No significant difference In survival, outcome or length of hospital stay was 
identified between the two groups, indicating that the presence or absence of 
an appropriate ischaemic lesion on CT scan following ischaemic lacunar 
stroke does not confer prognostic information after correcting for other factors 
known to influence outcome.
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other studies have examined the prognostic significance of visible cerebral 
infarction on CT scan following ischaemic s t r o k e h o w e v e r  the issue 
remains clouded due to small sample sizes and methodological differences 
between studies. The specific question of whether visible infarction increases 
the risk of poor outcome following lacunar stroke after correction for 
confounding factors has not yet been fully addressed in the literature as 
previously published studies have either examined only relatively small 
groups of lacunar stroke patients/^^ have collected limited follow-up data^^^ or 
have restricted the study to early imaging after s t r o k e . T h i s  study used a 
larger cohort of lacunar stroke patients than any yet published in the literature, 
and a single radiologist (unblinded to clinical information) interpreted the 
images. Although the cohort of patients studies was relatively large, one 
potentially-important confounding factor, the location of the lacunar lesion, 
was not examined. Lacunar syndromes may arise as a result of infarction in a 
variety of areas within both anterior (carotid) and posterior (vertebrobasilar) 
circulation territories. The study presented did not divide lacunar stroke 
patients according to the localisation of the lacunar lesion as the small 
numbers in each resultant sub-group would preclude any firm conclusions.
Reproducibility of radiological categorisation was not examined, and the 
absence of a measure of inter-observer variability could be criticised. 
Volumetric analysis of the radiological lesions was not performed as the small 
volumes involved would have resulted in the introduction of considerable 
error. Despite these weaknesses, the results obtained strengthen the 
conclusions of previous smaller studies which have reported similar findings
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but which have been criticised on the basis of small sample size or failure to 
correct for known prognostic factors.
8.06 Diffusion MRl o f Ischaemic Stroke at 1.0 Tesla
Chapter six describes the implementation of a novel diffusion-weighted 
magnetic resonance sequence on a standard 1.0 Tesla scanner. The potential 
advantages conferred by diffusion-weighted magnetic resonance techniques 
when applied to acute cerebral ischaemia have been recognised; however 
due to technical and financial constraints few centres in the United Kingdom 
use diffusion-weighted imaging to investigate stroke patients. We sought to 
further develop a pre-existing time-reversed steady-state (PSIF) diffusion- 
weighted sequence/®® and investigate its clinical usefulness when 
implemented on a standard MRl scanner.
Having optimised the sequence, a series of patients with acute stroke were 
scanned with both conventional and diffusion-weighted techniques. It was 
found that abnormalities on diffusion-weighted images were seen more 
frequently than on conventional (T2-weighted) images, and that the 
combination of diffusion-weighted and conventional sequences yielded more 
diagnostic information than the conventional sequences alone. Addition of the 
diffusion sequence to the conventional sequences prolonged the duration of 
the scan by approximately ten minutes. Repeat brain imaging performed at an 
interval confirmed localisation of ischaemic damage by the early diffusion- 
weighted MRl scan.
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With the advent of therapy for acute ischaemic stroke, the ability to depict 
ischaemic cerebral injury at an early stage has assumed increasing 
importance/®® In the United Kingdom, CT scanning is currently the most 
widely-used brain imaging technique after stroke. Although CT accurately 
detects the presence of intracerebral haemorrhage, the changes seen on CT 
scan early after ischaemic stroke are subtle and may be absent for several 
hours. Early, accurate identification, localisation and quantification of brain 
injury with diffusion-weighted MRl will enable early diagnosis and may have 
implications both for clinical trial design and provision of future therapies.
Using diffusion-weighted imaging, the effect of intervention with novel 
neuroprotective agents upon infarct volume can be studied. This will allow the 
use of a more rational endpoint in efficacy studies of neuroprotective drugs, 
and the avoidance of the confounding factors which may influence measures 
of clinical outcome.
The ability to localise cerebral infarction in the acute phase may influence 
choice of neuroprotective therapy. The differing pathophysiological 
mechanisms which underlie white and grey matter ischaemia are likely to 
necessitate different pharmacological approaches to therapy; early diftusion- 
weighted imaging may enable selection of an appropriate agent.
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A number of technical difficulties have been overcome to achieve the 
implementation of clinically-useful diffusion-weighted imaging on a standard 
1.0 Tesla scanner; further development of the sequence will be required to 
enhance the research potential of the technique. Diffusion tensor imaging and 
generation of apparent diffusion coefficient (ADC) maps are both theoretically 
possible with PSIF-based sequences; further work in this area is planned.
8.07 Thrombolytic Therapy for Acute Ischaemic Stroke in the UK
Chapter seven reports the implementation of thrombolytic therapy, the only 
treatment shown to influence outcome after ischaemic stroke, in a United 
Kingdom stroke centre. The continuous, prospective audit of process and 
outcome undertaken over more than two years examined fifteen recipients of 
thrombolytic therapy, and although the number of patients studied was 
insufficient to permit conclusions on safety and efficacy relative to published 
studies, the demographics and clinical characteristics of the treated patients 
have been identified.
The small number of recipients of thrombolytic therapy over a two-year period
reflects the low rate of early presentation to hospital with acute stroke. Very 
few patients currently present to hospital within three hours of onset of 
symptoms; the delay in presentation may arise as a result of failure to educate 
the public of the symptoms of stroke, failure of primary care physicians to 
promptly refer stroke patients to a specialist centre or reluctance of 
ambulance services to prioritise patients with stroke. Local variability in each
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of these factors is likely, and the changes necessary to improve the numbers 
of patients presenting early after stroke will vary between regions.
The audit has identified the need for close liaison with radiologists to minimise 
the time spent waiting for CT brain examination. A locally-agreed protocol 
with the radiology department of the Western Infirmary allowed prioritisation of 
potential recipients of rt-PA over requests for “routine” CT examinations: this 
enables prompt acquisition of the necessary imaging prior to administration of 
thrombolytic therapy.
From the audit it is apparent that the patients treated in Glasgow were older 
and more severely affected by the stroke than those patients reported in the 
literature/®^'^®® this difference again reflects patterns of presentation to 
hospital in that, at present, relatively few less severely affected patients reach 
hospital rapidly after onset of symptoms.
Although the use of thrombolytic therapy for acute ischaemic stroke is 
complicated by a number of logistic and clinical issues, we have found that 
patient outcomes and complication rates are similar to those reported by the 
NINDS investigators,^®^ whose protocol was employed (with minor 
modifications) in our unit. The numbers treated to date are too small to justify 
formal statistical analysis. The implementation of a protocol for thrombolytic 
therapy with rt-PA in a specialist UK stroke centre appears safe, but a 
continuous prospective audit of outcome is required to ensure that patients
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are not being exposed to unacceptable risk. Changes in the provision of acute 
care offered to stroke patients by relatives, primary care physicians, 
ambulance services and hospital staff will be required before thrombolytic 
therapy can be more widely used. These changes are likely to vary between 
regions and merit local investigation by all stroke centres intending to use 
thrombolytic therapy.
8.08 Conclusion
Acute treatment for ischaemic stroke is possible but at present its use is 
limited to a tiny minority of patients who present within three hours of onset of 
stroke to specialised stroke centres. More widespread implementation of 
diffusion-weighted magnetic resonance imaging may help in the identification 
of suitable recipients and allow safe use of thrombolytic therapy to be 
extended to other hospitals. This imaging modality may also facilitate the 
design and conduct of efficacy studies of other acute stroke therapies, for 
example intervention to control elevated blood glucose levels with sliding 
scale insulin. This technique has been shown to be feasible and safe; it could 
represent a further means of improving outcome after stroke and may be 
more widely applicable than other approaches due to the high proportion of 
stroke patients with hyperglycaemia early after symptom onset.
Secondary prevention of stroke should be considered in all stroke survivors.
The importance of safe and effective blood pressure control is recognised 
however in patients with carotid disease blood pressure reduction carries the
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risk of cerebral hypoperfusion. Angiotensin converting enzyme inhibitors have 
been shown to lower blood pressure without reducing cerebral blood flow in 
this group of patients; the generalised nature of atheromatous disease leads 
to the conclusion that screening for renal artery stenosis should be considered 
before they are used.
The role of lipid lowering therapy after stroke remains unclear. Data 
presented in this thesis suggest that the relationship between low triglyceride 
concentration and relatively poor outcome after stroke is stronger than the 
previously reported association between cholesterol concentration and 
outcome. This observation raises a number of questions concerning the 
precise effects of lipids and lipoprotein particles after stroke. Although the 
study presented can offer no immediate advice concerning treatment of lipids 
after stroke, it has accentuated the need for further mechanistic studies 
designed to clarify the observed relationships.
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Appendix One
Magnetic Resonance Imaging Using PSIF
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A1.1 Introduction
The technique used to provide the diffusion-weighted magnetic resonance 
images shown in chapter six is based upon a complex magnetic resonance 
sequence, termed a steady state free precession or reversed fast imaging 
with steady state precession ("PSIF") method. This appendix will provide a 
more detailed description of the basic mathematical and physical principles 
behind PSIF imaging.
The radiofrequency signal generated by tissue during a PSIF sequence
contains two components: a free induction decay (FID) that arises as a result
of the most recent radiofrequency pulse and a strongly T2 dependent spin-
echo component that forms immediately prior to the upcoming pulse as a
result of the cumulative effect of previous pulses. Because of the persistence
of the second signal, it is possible to use additional strong gradients in the
sequence to sensitise the image to the diffusion of water molecules. The spin-
echo component is intrinsically weak, and image generation is therefore
difficult using this component of the signal alone. Multiple acquisitions are
therefore needed to generate an image with adequate signal-to noise ratio.
The necessity for multiple acquisitions leads to a relatively long scan time in
comparison with, for example, echo-planar techniques. The design of the
sequence is such that the FID component of the signal is not used for 
,imaging.
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A1.2 Theory
pulse of the next TR cycle.
  ■ ■
A steady-state transverse magnetisation, Mxy, is generated when a 
succession of radiofrequency pulses, separated by a time interval TR, is 
applied to a tissue. The magnitude of the transverse magnetisation varies 
within each TR time interval as a function of tissue relaxation times and the 
flip angle of the radiofrequency pulses. From quantum theory any 
radiofrequency pulse flip angle can be described by the set of probabilities of 
any given proton in the tissue under study observing a 0°, 90° or 180° flip
angle (Table a 1.1). Therefore it is possible to construct combinations of these
observed flip angles which we can visualise as components of the total signal.
Typically it is appropriate to consider two components, since the others are of
such low statistical probability. Let us consider Mxy which is comprised of two
components. The first component represents the free induction decay
generated when tipping the longitudinal magnetisation (Mz) by 90°. This signal
decays toward the end of the time interval TR. The second component is
termed the spin echo. In contrast to the FID signal, the spin echo arises as a
result o f the combined effect of two consecutive radiofrequency pulses. The
90° component of the first RF pulse tips Mz to become Mxy. This magnetisation
\0dephases in the immediate TR interval until it is acted upon by the 180° 
component of the next RF pulse, which refocuses the dephased Mxy during
the next TR cycle. The echo may therefore be thought to be Mxy undergoing a 
T2 decay of two TR cycles when it is collected immediately before the RF
i
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A1.3 The PSIF Sequence
A labelled pulse sequence timing diagram of a non diffusion-weighted PSIF
sequence is shown in figure a1.1. Each component of the sequence is
described below.
A. A radiofrequency pulse is applied at a narrow frequency range to ensure 
that it is observed only by the desired tissue.
B. The slice select gradient selects a slice of tissue by sensitising it to the 
narrow range of frequencies within the radiofrequency pulse. The gradient 
resets immediately before application of the subsequent RF pulse.
C. To sample the data and produce an echo a read gradient is applied and 
reset after data acquisition.
D. A range of phase encoding gradients in the phase direction is applied and 
then, after data collection, is reset by a gradient applied in the opposite 
direction.
E. The echo generated by the tissue under study is recorded. The echo time 
(TE) is defined as the time from the RF pulse to the centre of the echo. In 
the case of PSIF, the “effective TE" is much longer since several repeats 
of TR are required to produce an echo. TE is therefore much longer than 
TR, hence the image is T2 weighted.
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Table A1.1 Quantum components of different flip angles
Flip angle 0° 90° 180°
0 1 0 0
180 0 0 1
90 0.5 1 0.5
45 0.854 0.707 0.146
135 0.146 0.707 0.854
1
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Figure A1.1 Pulse sequence timing diagram of PSIF sequence
A. RF
B. Slice select
C. Readout
a
.Jtl
D. Phase encode
E. Echo
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